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The genotoxicity of cobalt metal and cobalt compounds has been widely studied. Several publications
show induction of chromosomal aberrations, micronuclei or DNA damage in mammalian cells in vitro in
the absence of S9. Mixed results were seen in gene mutation studies in bacteria and mammalian cells
in vitro, and in chromosomal aberration or micronucleus assays in vivo. To resolve these inconsistencies,
new studies were performed with soluble and poorly soluble cobalt compounds according to OECD-
recommended protocols. Induction of chromosomal damage was conﬁrmed in vitro, but data suggest
this may be due to oxidative stress. No biologically signiﬁcant mutagenic responses were obtained in
bacteria, Tkþ/ or Hprt mutation tests. Negative results were also obtained for chromosomal aberrations
(in bone marrow and spermatogonia) and micronuclei at maximum tolerated doses in vivo. Poorly sol-
uble cobalt compounds do not appear to be genotoxic. Soluble compounds do induce some DNA and
chromosomal damage in vitro, probably due to reactive oxygen. The absence of chromosome damage in
robust GLP studies in vivo suggests that effective protective processes are sufﬁcient to prevent oxidative
DNA damage in whole mammals. Overall, there is no evidence of genetic toxicity with relevance for
humans of cobalt substances and cobalt metal.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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Cobalt metal has many important uses in industry. The most
important use of cobalt metal is as an alloying element in super-
alloys, magnetic and hard-metal alloys, such as stellite and
cemented carbides, cobalt-containing high-strength steels, elec-
trodeposited alloys and alloys with special properties. Cobalt salts
and oxides are used as pigments in the glass and ceramics in-
dustries, as catalysts in the oil and chemical industries, as paint and
printing ink driers and as trace metal additives for agricultural and
medical uses. Cobalt, in the form of cobalamin, is also an essential
trace element in human nutrition, as cobalt is found as the active
centre in cobalamin coenzymes. Given the widespread use of and
exposure to cobalt and cobalt compounds, its safety for humans is
of prime importance. The potential health hazards resulting from
exposure to cobalt compounds have recently been reviewed
(Paustenbach et al., 2013), but mainly focussed on the chemistry,
pharmacokinetics and systemic toxicity of cobalt. In this paper we
review the existing published genotoxicity data for cobalt sub-
stances and present diverse new experimental data from studies
with a variety of different cobalt substances that should be
considered in the overall assessment of cobalt and its genotoxic
potential.
2. Review of published data
The genotoxic potential of soluble cobalt compounds and cobalt
metal itself has been widely studied and reported.
2.1. Studies with bacteria
In terms of mutagenic activity in bacteria, Zeiger et al. (1992)
reported that cobalt sulphate heptahydrate was a weak
mutagen in Salmonella typhimurium strain TA100 when using the
pre-incubation method, and Pagano and Zeiger (1992) reported a
stronger mutagenic response for cobalt chloride in TA97, again
using the pre-incubation method with different aqueous solvents.
Cobalt chloride was also reported to be mutagenic in the absence
of S9 in strains TA98 and TA1537 using the plate incorporation
method (Wong, 1988). However, the range of concentrations used
was very toxic, no data from individual treatments were presented,
and the control revertant numbers for strains TA1535 and TA1537
were unusually high. For these reasons these ﬁndings are less
convincing. Cobalt metal itself was tested in S. typhimurium strains
TA98 and TA100, and in E. coli WP2uvrA/pKM101 as part of the
National Toxicology Program (NTP, 2013). No mutagenic responses
were observed in E. coli, either in the absence or presence of S9
using the pre-incubation method. An equivocal response was
observed in TA100 in the absence of S9, but mutagenic responses
that were weak and not well correlated with dose level were
observed in strain TA98 in the absence of S9. In a meeting abstract,
Turoczi et al. (1987) reported very weak to weak mutagenic effects
for cobalt acetate in 3 out of 5 Salmonella strains at a high dose
(10 mg/plate), but no details were given.
2.2. Studies in mammalian cells in vitro
Mixed results have been reported for mutagenic activity of co-
balt chloride in mammalian cells. Amacher and Paillet (1980)
found no induction of Tk mutations in mouse lymphoma cells
following 3-hrs treatment in the absence of metabolic activation.
However, there was no indication what levels of toxicity (if any)
these treatments induced, and the assay was not optimised to
detect small colonymutants. By contrast, Hartwig et al. (1990,1991)
and Miyaki et al. (1979) reported that cobalt chloride induced Hprtmutations in V79 cells after longer (20 or 24 h) treatment in the
absence of S9. Kitahara et al. (1996) reported that mutations were
induced in Chinese hamster ovary cells, transfected with a bacterial
gpt gene, by cobalt chloride and, to a lesser extent, by cobalt
sulﬁde.
There are surprisingly few published studies on induction of
chromosomal aberrations (CA) in mammalian cells with cobalt
compounds. Olivero et al. (1995) found a weak, but insigniﬁcant
induction of CA in human lymphocytes treated for 48 h in the
absence of S9 with cobalt chloride, but notwith cobalt sulphate or
nitrate. Paton and Allison (1972) also reported no induction of CA
by cobalt nitrate in two human cell lines, WI38 and MRC5, or in
human lymphocytes when treated in the absence of metabolic
activation for periods ranging from 2 to 24 h in the cell lines, and for
48 h in lymphocytes. However, the methods are far from standard
and the negative result must be viewed with caution. Figgitt et al.
(2010) used multicolour ﬂuorescence in situ hybridisation (M-
FISH) to show that divalent cobalt (cobalt chloride hexahydrate)
was a weak inducer of aneuploidy, but a very weak inducer of
chromosomal breaks in cultured human ﬁbroblasts.
There are, in contrast, many more publications on induction of
micronuclei (MN) in mammalian cells, most of which reported
positive results for ultraﬁne cobalt metal and soluble cobalt salts.
Daley et al. (2004) investigated MN induction in human lympho-
cytes by wear debris from hip or knee joints. The test material was
therefore not a pure chemical (titanium, vanadium, aluminium,
chromium, nickel and molybdenum were present) and therefore
the reported increases in MN frequency cannot be exclusively
attributed to cobalt. Van Goethem et al. (1997) reported signiﬁcant
induction of MN in human lymphocytes treated for short periods
(15 min) with low concentrations of ultraﬁne cobalt metal in the
absence of metabolic activation. These results were conﬁrmed by
De Boeck et al. (2003a) andMiller et al. (2001). As with the CA study
described above Olivero et al. (1995) reported weak induction of
MN in human lymphocytes treated with cobalt chloride, but not
with cobalt sulphate or nitrate. However, the MN response with
cobalt chloride was ﬂat (a plateau) whilst toxicity (mitotic inhibi-
tion) increased with concentration, making it difﬁcult to evaluate
the results. On the other hand, Ponti et al. (2009) did not detect
induction of MN in Balb/3T3 cells by concentrations of cobalt
chloride up to 10 mM, while Gibson et al. (1997) reported dose-
related induction of MN in Syrian hamster embryo (SHE) cells
treated with cobalt sulphate for 24 h in the absence of metabolic
activation.
There are several publications describing induction of direct
DNA damage in mammalian cells, mainly using the comet assay as
detection method. Caicedo et al. (2008), De Boeck et al. (1998),
Hartwig et al. (1990, 1991) and Ponti et al. (2009) all reported in-
duction of DNA damage by cobalt chloride in human Jurkat cells by
the neutral comet assay, in isolated human lymphocytes using the
alkaline comet assay, in HeLa cells by nucleoid sedimentation in
sucrose density gradients, and in Balb/3T3 cells by the comet assay,
respectively. De Boeck et al. (1998) and Van Goethem et al. (1997)
also reported induction of direct DNA damage with low concen-
trations of ultraﬁne cobalt metal in human leukocytes and blood
lymphocytes from three different donors using the alkaline version
of the comet assay, although in a later paper, De Boeck et al. (2003a)
were unable to reproduce the DNA damage responses. The differ-
ences did not appear to be due to particle size, cytotoxicity or
oxidised bases.
A publication by Ponti et al. (2009) describes the induction of
MN and DNA strand breaks (comet assay) in Balb/3T3 cells by cobalt
nanoparticles. The induction of DNA damage appears to be due to
oxidative stress caused by the nanoparticles according to Alariﬁ
et al. (2013). However, nanosized cobalt is not commonly
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studies presented here did not include testing of cobalt
nanoparticles.
2.3. In vivo studies
A small number of publications have reported on investigations
of genotoxicity in somatic cells in vivo and have givenmixed results.
Palit et al. (1991) reported dose- and time-related increases in CA
frequency in the bone marrow of groups of mice dosed orally with
cobalt chloride hexahydrate. Different sampling times (6, 12, 18
and 24 h) were included in this study to allow for the different
kinetics and metabolism of other different chemicals included in
the study. It is most unusual for genotoxins to produce dose-related
responses at all sampling times tested, and the results are therefore
difﬁcult to interpret. Farah (1983) reported increased hyperdiploid
and pseudodiploid cells in the bone marrow of male Syrian ham-
sters dosed intraperitoneally on ﬁve consecutive days with cobalt
chloride. Since control levels of hyperdiploid cells were high, the
deﬁnition of pseudodiploid cells is unclear, and there was no
measure of bone marrow toxicity, these results are difﬁcult to
interpret.
By contrast, high oral doses (probably above the maximum
tolerated dose) of cobalt chloride hexahydrate gave negative re-
sults at 2 different sampling times when tested for induction of CA
andMN in rat bonemarrow (Gudi and Ritter,1998). Some reduction
in mitotic index and marked reduction in percent polychromatic
erythrocytes (PCE) indicated systemic (and therefore bonemarrow)
exposure. Although the extent of bone marrow toxicity may have
prevented some damaged cells from dividing and producing MN at
the later (42 h) sampling time, the negative MN responses at 18 h
and the negative CA responses at both sampling times indicate a
robust assessment.
Also, lethal doses of cobalt 2-ethyl hexanoate gave negative
results when tested for MN induction in CD-1mice that were dosed
orally on 2 consecutive days, 24 h apart (Richold et al., 1981).
Although there was no clear evidence of bone marrow toxicity,
signs of systemic exposure (hypopnoea, lethargy and piloerection)
were seen at several doses.
In an abstract, Turoczi et al. (1987) reported that cobalt acetate
did not induce MN in mouse bone marrow after intraperitoneal
dosing. No details of numbers of animals, sampling times or cells
scored are given, and therefore this negative result has to be viewed
with considerable caution. At the end of a 13-week (5 days per
week) inhalation study with ﬁve different doses of cobalt metal
powder, NTP (NTP, 2013) reported no increases in MN in normo-
chromatic erythrocytes (NCE) of mice. There was no evidence of
bone marrow toxicity. However, at the same time, toxicokinetic
experiments demonstrated systemic exposure. By contrast, a recent
paper by Rasgele et al. (2013) reported signiﬁcant induction of MN
in bone marrow of mice treated intraperitoneally with cobalt
chloride. Mice were sacriﬁced 24 and 48 h after injection and there
were statistically signiﬁcant increases in MN frequency at the top
two doses of cobalt chloride at 24 h, and at all three doses (but not
dose-related) at 48 h. There was no evidence of bone marrow
toxicity (based on PCE:NCE ratio) at any dose level, although the
ratio in control animals was higher than usually experienced. Also,
a single intraperitoneal injection of cobalt chloride in BALB/c mice
caused an increase in MN formation (Suzuki et al., 1993). However,
in both of these studies with cobalt chloride, the increased MN
frequencies may be due to stimulation of erythropoiesis, as has
been described by Goldwasser et al. (1958).
Only one publication reported relevant results on genotoxic
effects in germ cells. Farah (1983) studied the effects of cobalt
chloride for induction of numerical chromosomal aberrations inmetaphase I and II meiotic testicular cells of male Syrian hamsters
using the same protocol as for measurement of CA in bone marrow,
discussed above. An increase in cells with at least 23 bivalents
(instead of the normal 22) was seen in metaphase I preparations
from the treated group. Based on the shortcomings mentioned
above, the relevance of these results is difﬁcult to assess.
There is one relevant study on humans. De Boeck et al. (2000)
integrated different methods to assess both initial DNA damage
(urinary excretion of 8-hydroxyguanosine and DNA migration in
lymphocytes) and deﬁnitive chromosome breakage or loss
(micronuclei in lymphocytes) in 35 workers from cobalt reﬁneries
and in 29workers of hardmetal production sites. Theworkers were
exposed to an average cobalt dust concentration of 20 mg/m3
(estimated by the urinary concentration of 20 mg Co/g creatinine),
which is equivalent to the current ACGIH threshold limit value
(TLV-TWA). No signiﬁcant increase in any genotoxicity biomarker
was found in exposed workers when compared with matched
controls nor in hard metal dust exposed workers when compared
to cobalt exposed workers.
Thus, the published studies on genotoxicity of soluble cobalt
compounds (such as cobalt chloride, cobalt sulphate) and cobalt
metal show some inconsistent results. Both positive and negative
ﬁndings have been reported for mutation in bacterial and
mammalian cells, and for induction of CA and MN both in vitro and
in vivo, although the increased MN frequencies in bone marrow
cells in vivomay be due to stimulation of erythropoiesis. In order to
try to resolve these inconsistencies, new studies for these end-
points have been performed using well-characterised samples of
cobalt test substances, including poorly soluble cobalt compounds,
and carried out according to current (OECD-recommended) pro-
tocols. The results are presented here and are discussed in the light
of the published ﬁndings.
3. Materials and methods
3.1. Test chemicals
In the materials and studies described below we refer to cobalt
metal powder or ultraﬁne cobalt metal powder. The cobalt metal
powders or particles used in these studies cannot be considered to
be nanoparticles. In all studies, a “ﬁne cobalt powder” by Umicore
was used. There were slight, batch-dependent, differences in the
particle size distributions (PSDs) between the powders used for the
Hprt and for the bacterial mutagenicity (Ames) studies. Below, for
each batch, the PSDs are given by specifying the D50, the median,
deﬁned as the diameter where half of the particle population lies
below this value (that is, half of the particle population is smaller
than the median sized particle). Similarly, 90 percent of the particle
population is smaller than the D90, and 10 percent of the popula-
tion lies below the D10.
Further, the total particle population is characterised below
expressed as the distributions by % volume. For example, 47.6% of
the particles (Hprt Studies), are in the size range of between 2 and
4 mm. Only 0.2% and 0.5% of the particles in the Hprt and in the
Ames tests, respectively, are in the size range of smaller than 1 mm.
Whilst it is possible that the “smaller than 1 mm fraction” contains
particles smaller than 100 nm (“nanoparticles”), a powder with the
below PSD characteristics is not considered a “nanoparticle” pow-
der, since the vast majority (99.8% and 99.5%) of the particles
constituting these powders are in the micron range.
Laser diffraction analysis of Umicore ﬁne cobalt powder e ul-
traﬁne, as used in Ames tests:
 D10 e 1.6 mm
 D50 e 2.9 mm
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 þ10 mm fraction e 0.0 volume%
 10 þ8 mm fraction e 0.0 volume%
 8 þ6 mm fraction e 4.2 volume%
 6 þ4 mm fraction e 19.9 volume%
 4 þ2 mm fraction e 52.3 volume%
 2 þ1 mm fraction e 23.1 volume%
 1 mm fraction e 0.5 volume%
Laser diffraction analysis of Umicore ﬁne cobalt powder e ul-
traﬁne, as used in Hprt studies:
 D10 e 1.8 mm
 D50 e 3.4 mm
 D90 e 6.2 mm
 þ10 mm fraction e 0.0 volume%
 10 þ8 mm fraction e 2.0 volume%
 8 þ6 mm fraction e 9.6 volume%
 6 þ4 mm fraction e 25.8 volume%
 4 þ2 mm fraction e 47.6 volume%
 2 þ1 mm fraction e 14.8 volume%
 1 mm fraction e 0.2 volume%
For the bacterial mutation tests ultraﬁne cobalt metal powder
(99.94% pure), cobalt chloride (>99% pure) and cobalt sulphate
(>99.9% pure) were obtained from Umicore Cobalt and Specialty
Materials (CSM), Watertorenstraat 33, 2250 Olen, Belgium.
For Ames, mouse lymphoma Tk mutation and in vitro CA assays
in human lymphocytes, cobalt resinate (83.7%, 83.1% and 83.7%
pure for the 3 assays respectively) and cobalt acetyl acetonate
(98.9%, 99.4% and 98.9% pure for the 3 assays respectively) were
obtained from Michelin, Clermont-Ferrand, France.
For the mammalian cell Hprt gene mutation studies, tricobalt
tetraoxide (cobalt content 73.43%), cobalt sulphate (99.9% pure),
cobalt oxalate (100% pure) and cobalt metal powder (99.98%
pure) were obtained from Umicore Cobalt and Specialty Materials
(CSM), Watertorenstraat 33, 2250 Olen, Belgium. Lithium cobalt
dioxide (cobalt content 60.2%) was obtained from Umicore Korea
Limited, Chunan-City, Chungnam, 330-200, Korea. Cobalt 2-ethyl
hexanoate (cobalt content 16.6%) was obtained from Rockwood
Pigments UK Ltd., County Durham DH3 1QX, England. Cobalt oxide
hydroxide (cobalt content 60.49%) was obtained from QNI Tech-
nology, Greenvale Street, Yabulu Via Townsville, Queensland 4818
Australia. Cobalt sulphide (100% pure) was obtained fromVale Inco
Ltd., Port Colborne, Canada. Cobalt monoxide (99.998% pure) was
obtained from Alfa Aesar, Johnson Matthey, Ward Hill, MA 01835-
8099, USA. Cobalt borate neodecanoate (100% pure) was obtained
from OMG OMGroup, OMG Borchers GmbH, Berghausener Str. 100,
40764 Langenfeld, Germany. Cobalt dihydroxide (100% pure, co-
balt content 62.3%) was obtained from OM Group, OMG Kokkola
Chemicals OY, 67101 Kokkola, Finland.
For the in vitro CA study in V79 cells, cobalt oxyhydroxide
(cobalt content 60.49%) was obtained from QNI Technology,
Greenvale Street, Yabulu Via Townsville, Queensland 4818,
Australia.
For the in vitro studies on oxidative damage (induction of
reactive oxygen species and modiﬁed comet assay), cobalt octoate
(cobalt content 17%) was obtained from Umicore Specialty Mate-
rials Brugge, Kleine Pathoekeweg 82, 8000 Brugge, Belgium and
cobalt sulphate heptahydrate (cobalt content 21%) was obtained
from Umicore Cobalt & Specialty Materials, Watertorenstraat 33,
2250 Olen, Belgium.
For the in vivoMN studies, cobalt acetyl acetonate (98.9% pure)
and cobalt resinate (83.7% pure) were obtained from Michelin,
Clermont-Ferrand, France.For the in vivo CA assays, cobalt sulphate (cobalt content 21%)
and tricobalt tetraoxide (cobalt content 73.43%) were obtained
from Umicore Leemanslaan 36, Olen, Belgium 2250, and cobalt
monoxide (cobalt content 78.2%), was obtained fromOMG Kokkola
Chemicals Oy, Kokkola, Finland.
For the in vivo spermatogonial CA study, cobalt dichloride
hexahydrate (cobalt content 24.74%) was obtained from Umicore
Cobalt and Specialty Materials (CSM), Watertorenstraat 33, 2250
Olen, Belgium.
Positive control and other reference chemicals of the highest
purity available were obtained as follows:
 4-nitro-o-phenylenediamine (4NOPD) and ethyl methanesul-
fonate (EMS) from SigmaeAldrich, 82024 Taufkirchen, Germany
 2-aminoanthracene (2-AA) from SigmaeAldrich, 82024 Tauf-
kirchen, Germany, from SigmaeAldrich, Poole, Dorset, UK and
also from Trinova Biochem GmbH, 35394 Gieben, Germany
 Sodium azide (NaN3), 2-nitroﬂuorene (2NF), benzo(a)pyrene (B
[a]P) and 9-aminoacridine (9AA) from Trinova Biochem GmbH,
35394 Gieben, Germany and from SigmaeAldrich, Poole, Dorset,
UK.
 Methyl methanesulfonate (MMS) and mitomycin C (MMC) from
SigmaeAldrich, Saint-Quentin Fallavier, France
 Cyclophosphamide (CPA) from SigmaeAldrich, Saint-Quentin
Fallavier, France, from SigmaeAldrich, 82024 Taufkirchen, Ger-
many and also from SigmaeAldrich, Oakville, Ontario, Canada
 4-nitroquinoline-1-oxide (NQO) from SigmaeAldrich, Poole,
Dorset, UK
 3-morpholinosydnonimine hydrochloride (SIN-1) and triton X-
100 from SigmaeAldrich, Germany
 Quartz, type DQ12, mid-size D€orentrup, from Bergbauforschung
Essen, Germany, geometric mean diameter, weighting by mass:
3.01 ± 1.53 mm, 87% a quartz, 13% amorphous
 Potassium bromate (KBrO3) from Merck, Darmstadt, Germany
 Aluminium oxide (Al2O3), fused, from SigmaeAldrich, 82024
Taufkirchen, Germany, sized in a water column, resulting in a
geometrical mean diameter, weighting by mass: 4.09 ± 1.77 mm
 1,2-dimethylhydrazine monohydrate (DMH) from Sigma-
eAldrich, Oakville, Ontario, Canada
For the mammalian cell gene mutation studies tri-
ﬂuorothymidine (TFT) was obtained from SigmaeAldrich, Saint-
Quentin Fallavier, France and 6-thioguanine (6 TG) was obtained
from SigmaeAldrich, Poole, Dorset, UK.
For the production of reactive oxygen species (ROS) in vitro,
20,7'-dichloroﬂuorescein diacetate (DCFH-DA) was obtained from
SigmaeAldrich, 82024 Taufkirchen, Germany. Hank's salt solution
(HBSS), without phenol red was obtained from Biochrom GmbH,
12247 Berlin, Germany.
3.2. Rat liver S9
The rat liver S9 used in the bacterial mutation studies was either
prepared in-house from Aroclor-1254 or phenobarbital/b-naph-
thoﬂavone pre-treated rats according to Maron and Ames (1983),
with a minimum protein content of 33 mg/mL, or was obtained
from Molecular Toxicology Inc. (Boone, North Carolina, USA). The
S9 was mixed with standard cofactors for use in the individual
assays as described below.
For the mouse lymphoma Tk and Hprtmutation studies, and for
the in vitro CA tests in human lymphocytes, Aroclor-induced S9 was
purchased from Molecular Toxicology Inc. (Boone, North Carolina,
USA). It was mixed with standard cofactors (glucose-6-phosphate,
NADP and KCl) to give a ﬁnal concentration in the treatment me-
dium of 2% for the gene mutation studies and a ﬁnal concentration
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For the in vitro CA study in V79 cells, S9 was prepared at BSL
BioService GmbH, Germany, from male Wistar rats that had been
induced with phenobarbital (80 mg/kg) and b-naphthoﬂavone
(100 mg/kg). The protein content was 33 mg/mL. After mixing with
co-factors the ﬁnal concentration of S9 in the treated cultures was
2.27%.
3.3. Ames tests
3.3.1. Single strain tests
In light of the published positive results with cobalt metal,
cobalt chloride and cobalt sulphate, a series of GLP studies were
performed in order to investigate the bacterial strains that had
shown evidence of potential mutagenic effects. Cobalt metal was
tested in S. typhimurium strain TA98, cobalt chloride was tested in
strain TA97a and cobalt sulphate was tested in strain TA100, and
each substance was tested in three different laboratories.
The bacteria used were obtained from different sources as
follows:
 For Flügge (2013a,b,c) and Laboratory 3, the 3 bacterial strains
were all obtained from Trinova Biochem GmbH, 35394 Gieben,
Germany, who originally obtained the strains from Prof. B.N.
Ames.
 For Laboratory 2, strain TA100 was obtained from Covance
Laboratories Inc., Vienna, Virginia, USA, strain TA97a was ob-
tained from Glaxo Group Research, Ware, Hertfordshire, UK, and
strain TA98 was obtained from the National Collection of Type
Cultures, Public Health England, Porton Down, Salisbury, Wilt-
shire, UK. In each case the strains were originally obtained from
Prof. B.N. Ames.
All strains were regularly checked for membrane permeability
(rfamutation), ampicillin resistance, UV sensitivity, and amino acid
requirement as well as normal spontaneous mutation rates.
The following positive control chemicals were used by the
participating laboratories:
 For strain TA98, 2NF at 5 or 10 mg/plate or 4NOPD at 10 mg/plate
in the absence of S9, and B[a]P at 10 mg/plate or 2-AA at 2.5 mg/
plate in the presence of S9
 For strain TA97a, 9AA at 100 mg/plate or 4NOPD at 10 mg/plate in
the absence of S9, and 2-AA at 2, 2.5 or 5 mg/plate in the pres-
ence of S9
 For strain TA100, NaN3 at 2 or 10 mg/plate in the absence of S9,
and 2-AA at 2, 2.5 or 5 mg/plate in the presence of S9
Some details of the methods used by the 3 laboratories were
slightly but not dramatically different. The different approaches
may be summarised as follows:
 All 3 laboratories corrected for the water content of cobalt
chloride hexahydrate and cobalt sulphate heptahydrate in
determining the concentrations tested on each plate. However,
although all 3 laboratories suspended cobalt powder in anhy-
drous analytical grade DMSO, cobalt sulphate and cobalt chlo-
ride were dissolved in deionised water in one laboratory but
were dissolved in DMSO in the other 2 laboratories.
 All 3 laboratories performed 2 independent experiments in the
absence and presence of S9, but Laboratory 3 also performed
additional experiments with cobalt chloride and cobalt
sulphate.
 Induced rat liver S9 was mixed with standard co-factors (MgCl2,
KCl, glucose-6-phosphate and NADP in phosphate buffer) foruse. Flügge (2013a,b,c) used 5% S9 mix whereas the other two
laboratories used 10% S9 mix.
 All 3 laboratories performed the ﬁrst experiment using the plate
incorporation method (Maron and Ames, 1983). Flügge
(2013a,b,c) and Laboratory 3 performed the whole of the sec-
ond experiment using the pre-incubation method (Yahagi et al.,
1975), whereas Laboratory 2 performed the treatments in the
absence of S9 using the plate incorporation method and only
used the pre-incubation method for the treatments in the
presence of S9. The additional experiments performed by Lab-
oratory 3 included both plate incorporation and pre-incubation
methods in the absence and presence of S9.
 Each laboratory tested at least 6 concentrations of each test
chemical in each part of the study, and each treatment was
carried out at least in triplicate. The top concentration was
usually 5000 mg/plate, but in some cases precipitation dictated
that a slightly lower top concentration was used.
 Flügge (2013a,b,c) tested the same range of concentrations in
each of the 2 experiments. Laboratory 3 tested similar ranges of
concentrations in all experiments, although the top concentra-
tion was lower for one of the pre-incubation experiments.
Laboratory 2 chose a narrower range of concentrations for the
second experiment.
Following incubation for 2e3 days at 37 C in the dark, the
plates were examined for signs of toxicity to the background lawn
and revertant colonies were counted electronically using a Petri
Viewer Mk2 or Sorcerer Colony Counter (Perceptive Instruments
ltd, UK), or with a Biocount 5000g (Bio-Sys GmbH, Kiefernweg 10,
61184 Karben, Germany). Where confounding factors affected the
accuracy of the automated counter, plates were counted manually.
The means and standard deviations were determined for each
treatment concentration.
The 3 laboratories used slightly different approaches to the
evaluation of the data in terms of deﬁning a positive response. In
summary they were:
 Flügge (2013a,b,c) concluded a positive response if the number
of revertants was signiﬁcantly increased (p  0.05, U-test ac-
cording to Mann and Whitney) compared with the solvent
control to at least 2-fold of the solvent control in both inde-
pendent experiments; a signiﬁcant (p 0.05) concentration (log
value)-related effect (Spearman's rank correlation coefﬁcient)
was observed; and positive results were reproducible and the
histidine independence of the revertants was conﬁrmed by
streaking random samples on histidine-free agar plates.
 Laboratory 2 concluded a positive if there was a concentration
related increase in revertant numbers to 2.0-fold the concur-
rent vehicle control values and positive trend/effects were
reproducible.
 Laboratory 3 concluded a positive response if a biologically
relevant increase in the number of revertants exceeding the
threshold of twice the colony count of the corresponding sol-
vent control was observed, or if a dose-dependent increase
above the 2-fold threshold was seen at more than one concen-
tration, or if an increase exceeding the 2-fold threshold at only
one concentration was reproduced in an independent second
experiment.
Thus, the common factors which have been applied in the
evaluation of data for these single strain experiments were that a
test substance was judged to be mutagenic if it produced, for at
least one concentration, a response equal to at least 2x the control
incidence of revertants, a dose-related trend was observed, and the
effects were reproducible.
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GLP studies in 5 strains of S. typhimurium (TA98, TA100, TA102,
TA1535 and TA1537, obtained from Prof. B.N. Ames, Berkeley, Cal-
ifornia) were performed with cobalt resinate and cobalt acetyl
acetonate. Strain-speciﬁc positive control chemicals were included
in the absence of S9 and 2-AA was used as positive control in the
presence of S9.
Cobalt resinate was dissolved in tetrahydrofuran, and cobalt
acetyl acetonate was suspended in tetrahydrofuran (Carlo Erba, Val
de Reuil, France). Both were tested in the absence and presence of
induced rat liver S9 (10% ﬁnal concentration) in 2 independent
experiments. The plate incorporation method was used for treat-
ments in the absence and presence of S9 in Experiment 1, and for
treatments in the absence of S9 in Experiment 2, but treatments in
the presence of S9 in Experiment 2 were performed using a 60 min
pre-incubation prior to plating. At least 5 concentrations of each
chemical were evaluated in triplicate plates in each part of the
study. Both compounds produced precipitate, and so the top con-
centration tested for both compounds was 1000 mg/plate. Some
precipitate was seen either in the tubes or on the plates at con-
centrations of 250 or 500 mg/plate for cobalt resinate and cobalt
acetyl acetonate respectively.
A positive result was deﬁned by a reproducible 2-fold (for
strains TA98, TA100 and TA102) or 3-fold increase (for strains
TA1535 and TA1537) in the number of revertants compared with
the vehicle controls at any dose-level, and/or evidence of a dose-
response.
3.4. Mammalian cell gene mutation tests
3.4.1. Mouse lymphoma tk mutation tests
L5178Y Tkþ/ cells were obtained from ATCC (American Type
Culture Collection, Manassas, USA), through Biovalley (Marne-La-
Vallee, France). The cells were stored at 80 C in cryoprotective
medium containing 10% horse serum and 10% dimethylsulfoxide
(DMSO). Each batch of frozen cells was purged of spontaneous Tk/
 mutants and checked for the absence of mycoplasma. The cells
were maintained in ﬂasks as suspension cultures in RPMI 1640
culture medium containing L-glutamine (2 mM), penicillin (100 U/
mL), streptomycin (100 mg/mL) and sodium pyruvate (200 mg/mL)
and supplemented with heat inactivated horse serum in a 37 C, 5%
CO2 humidiﬁed incubator. For suspension growth and for the 24 h
treatments the medium was supplemented with heat inactivated
horse serum at 10%, v/v, for the 3 h treatments it was 5%, v/v, and for
plating for viability and mutant selection it was 20%, v/v.
Cobalt resinate was dissolved in tetrahydrofuran and tested
using the microwell method. Treatments were for 3 h and 24 h in
the absence of S9, and for 3 h (2 experiments) in the presence of S9.
The compound precipitated in culture medium and persisted to the
end of treatment at concentrations of 25 mg/mL and higher for the
3 h treatments and at 50 mg/mL and higher for the 24 h treatment.
However, 100 mg/mL was chosen as the top concentration in all of
the main mutation experiments in order to try to achieve accept-
able levels of toxicity.
Cobalt acetyl acetonatewas suspended in tetrahydrofuran, but
the maximum concentration that produced a homogeneous sus-
pension gave, after dilution in culture medium, a top concentration
of 91.625 mg/mL. This concentration did not produce precipitate in
the ﬁnal treatment medium, but it did induce toxicity (at least 60%
reduction in relative total growth, RTG). The microwell method was
again used, and treatments were for 3 h in the absence or presence
of S9 in 2 independent experiments. In light of the results after 3 h
it was not necessary to also treat for an extended 24 h in the
absence of S9.
MMS (25 mg/mL for 3 h treatments and 5 mg/mL for 24 htreatments) and CPA (3 mg/mL) were used as positive control
treatments in the absence and presence of S9 respectively.
For the 3-hr treatments, 20 mL cultures (5  105 cells/mL) were
treated in 50 mL tubes. For the 24-hr treatments, 50 mL cultures
(2  105 cells/mL) were treated in ﬂasks which were gently shaken
at least once. At the end of the treatment period, the cells were
rinsed, centrifuged, the supernatant removed, the pellets sus-
pended in medium and the cells counted using a haemocytometer.
The cell concentrations were adjusted to 2  105 cells/mL and
maintained close to this density during the 48 h expression period,
at the end of which cells were counted and seeded into microwell
plates as follows:
 Viability plates e to deﬁne the number of viable cells (CE2:
Cloning Efﬁciency at the end of the expression period), an
average of 1.6 cells/well were seeded in two 96-well plates/
culture (4 plates/dose-level). After at least 7 days of incubation,
in a 37 C, 5% CO2 humidiﬁed incubator, the clones were
counted.
 Mutant selection plates e to select the TFTR (triﬂuorothymidine
resistant) mutant cells (for the determination of CEmutant),
2000 cells/well were seeded in four 96-well plates/culture (8
plates/dose-level). After 11e12 days of incubation in a 37 C, 5%
CO2 humidiﬁed incubator in the presence of 4 mg TFT/mL of
culture medium, the clones were counted, differentiating small
and large colonies as follows:
 Size of small colonies: < 25% of the diameter of the well,
 Size of large colonies: > 25% of the diameter of the well.
For scoring of colonies in mutant plates, the following param-
eters were considered:
 Well containing mutant colony (small or large),
 Well not containing mutant colony.
When both small and large colonies were present in the same
well, both mutant colonies were counted (one small and one large).
Cloning efﬁciency, suspension growth, adjusted relative total
growth and mutant frequency were calculated using standard
formulae as described by Mei et al. (2014).
IWGT recommendations (Moore et al., 2003, 2006, 2007) were
followed for the determination of a positive result, namely:
 For at least one concentration the induced mutant frequency
(mutant frequency treated minus mutant frequency of the
vehicle control) equalled or exceeded the Global Evaluation
Factor (GEF) of 126  106,
 A dose-response was demonstrated by a statistically signiﬁcant
trend test (in this case using the Kendall rank correlation
coefﬁcient).3.4.2. Hprt mutation tests in mouse lymphoma cells
Ten different cobalt salts/compounds, plus cobalt metal powder
and an extract of cobalt metal powder, were tested for induction of
Hprt mutations in mouse lymphoma L5178Y cells. Concentrations
for the mutation experiments were selected after range-ﬁnding
experiments and top concentrations were based on solubility
limits or cytotoxicity as described below. In each mutation study
the chemicals were tested for 3 h in the absence and presence of S9.
At least 2 independent experiments were performed, but occa-
sionally additional experiments were performed for clariﬁcation of
results. Although not required according to OECD guideline 476, an
extended 24 h treatment in the absence of S9 was performedwith 5
of the test substances in order to detect any mutagenic effects that
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cell cycle.
The 7 substances that were tested only for 3 h in the absence
and presence of S9 were prepared and tested as follows:
 Cobalt dihydroxide was suspended in 0.5% methyl cellulose
(MC) and diluted 10-fold into culture medium. It was toxic at
low concentrations, inducing >80% reduction in relative survival
in the range 19e35 mg/mL where no precipitation was seen.
 Lithium cobalt dioxide was suspended in 0.5% MC and diluted
10-fold into culture mediumwhere it precipitated and persisted
to the end of treatment at concentrations of 50e60 mg/mL (the
top concentrations chosen for the mutation experiments) and
higher. Due to a formulation error, concentrations up to 600 mg/
mL were tested in the presence of S9 in the ﬁrst experiment, but
although no precipitate was visible at lower concentrations the
cell pellets were discoloured when treatment medium was
removed after 3 h. Therefore the solubility limit was almost
certainly exceeded in this experiment. None of the treatments
induced signiﬁcant toxicity (maximum 22% reduction in relative
survival).
 Cobalt oxide hydroxide was suspended in 0.5% MC and diluted
into culture medium. The top concentrations in each experi-
ment were the lowest that produced persistent precipitate
through the treatment period, namely 15 and 12.5 mg/mL in both
the absence and presence of S9 in the 2 main experiments
respectively. None of the treatments induced signiﬁcant toxicity
(maximum 18% reduction in relative survival).
 Cobalt oxalate was suspended in 0.5% MC and diluted 10-fold
into culture medium where it precipitated and persisted to the
end of treatment at concentrations of 70 mg/mL and higher. It
was toxic at this and lower concentrations, inducing >80%
reduction in relative survival at 55 mg/mL in the absence of S9,
and at 60 or 70 mg/mL in the presence of S9. Therefore most
concentrations evaluated for mutations were soluble.
 Cobalt metal powder was suspended in 0.5% MC at a series of
concentrations which were each diluted 10-fold into the cul-
tures for treatment. Undissolved cobalt metal powder was
present at many lower concentrations. It was also toxic at lower
concentrations, inducing >80% reduction in relative survival at
37.5e40 mg/mL in the absence of S9, and at 40e200 mg/mL in the
presence of S9, and so these lower concentrations were evalu-
ated for mutations. There was marked variability in the toxic
responses in the presence of S9 between the different experi-
ments which may be a reﬂection of the fact that undissolved
cobalt metal powder was present, and may have exerted toxic
effects on the cells due to its physical presence.
 Tricobalt tetraoxide was dissolved in DMSO at a series of con-
centrations which were diluted 100-fold into the cultures for
treatment. The top concentrations in each experiment were
observed to be the lowest producing persistent precipitate
through the treatment period, namely 2000 and 2408 mg/mL in
the absence of S9, and 600 and 750 mg/mL in the presence of S9.
None of these induced signiﬁcant toxicity (maximum 34%
reduction in relative survival).
 Cobalt 2-ethyl hexanoate was dissolved in DMSO at a series of
concentrations which were diluted 100-fold in culture medium.
It was toxic at low concentrations, inducing >80% reduction in
relative survival in the range 80e120 mg/mL, and therefore all
concentrations evaluated for mutations were soluble.
The 5 substances that were tested both for 3 h in the absence
and presence of S9, and for 24 h in the absence of S9, were prepared
as follows: Cobalt sulphate was dissolved in water at a series of concen-
trations and diluted in culture medium. It was toxic at low
concentrations, inducing >80% reduction in relative survival at
50e100 mg/mL for the 3 h treatments, and at 35 mg/mL for the
24 h treatment. Therefore all concentrations evaluated for mu-
tations were soluble.
 Cobalt sulphidewas suspended in 1.0% carboxymethyl cellulose
at a series of concentrations and diluted 10-fold in culture me-
dium. For the 3 h treatments it was possible to achieve a top
concentration of 10mM (922 mg/mL), whichwas not toxic, and is
the maximum required for testing of nonetoxic chemicals. It
exhibited some toxicity following 24 h treatments, and so the
maximum concentration (that reduced relative survival to 11%
of controls) in this part of the study was 800 mg/mL.
 Cobalt monoxide was suspended in 0.5% MC and diluted 10-
fold into culture medium where it precipitated and persisted
to the end of treatment at concentrations of 60e80 mg/mL and
higher. Following 3 h treatments, signiﬁcant (86%) toxicity was
induced at 80 mg/mL in the absence of S9 in the ﬁrst experi-
ment, but at 60 mg/mL (the top concentration for the second
experiment in the absence of S9 and both experiments in the
presence of S9) only slight to moderate (15e41%) toxicity was
induced. It was also toxic following 24 h treatments in the
absence of S9, and the top concentration tested for mutation
induction was 60 mg/mL, which induced 90% reduction in
relative survival.
 Cobalt borate neodecanoate was dissolved in tetrahydrofuran
and diluted 200-fold into the cultures for treatment. Based on
range-ﬁnding data the top concentrations used in the mutation
experiments were 100 mg/mL for the 3 h treatments and 7.5 mg/
mL for the 24 h treatment.
 An extract of cobalt metal powder was prepared by incu-
bating the powder in RPMI 5 medium (i.e. RPMI 1640 medium
containing 5% heat-inactivated horse serum, plus 100 units/mL
penicillin, 100 mg/mL streptomycin, 2.5 mg/mL amphotericin B
and 0.5 mg/mL pluronic) for approximately 72 h at 37 C, with
shaking. The resultant suspension was then centrifuged at
1000 g for 10 min and the supernatant decanted for treatment
of the cells (see below). Concentrations were expressed ac-
cording to the amounts of cobalt metal powder added to the
extraction medium and the top concentration was therefore
589.3 mg/mL (equivalent to 10 mM). Tyndall analysis
(measuring LASER light scattering) was performed for 60 min
at 5 min intervals during the range-ﬁnding experiment to
ensure the level of any residual particulate matter was at an
acceptable level, indicating that the formulation sample was
suitable for testing.
L5178Y Tkþ/ 3.7.2C mouse lymphoma cells originated from Dr
Donald Clive, Burroughs Wellcome Co., USA. Cells were stored as
frozen stocks in liquid nitrogen. Each batch of frozen cells was
purged of mutants and conﬁrmed to be mycoplasma free. For each
experiment, at least one vial was thawed rapidly, the cells diluted in
RPMI 10 culture medium (i.e. RPMI 1640 medium containing 10%
heat-inactivated horse serum, plus 100 units/mL penicillin, 100 mg/
mL streptomycin, 2.5 mg/mL amphotericin B and 0.5 mg/mL plur-
onic) and incubated in a humidiﬁed atmosphere of 5% CO2 in air.
When the cells were growing well, subcultures were established in
an appropriate number of ﬂasks.
Treatment and post treatment dilution of cell cultures for the
cytotoxicity range-ﬁnding experiments was as described below for
themutation experiments. However, single cultures only were used
and positive controls were not included. Osmolality and pH mea-
surements were made on post-treatment media. Cell concentra-
tions were adjusted to 8 cells/mL and, for each concentration,
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determination of relative survival. The plates were incubated at
37 C in a humidiﬁed incubator gassed with 5% CO2 in air for 7 days.
Wells containing viable clones were identiﬁed by eye using back-
ground illumination and counted.
For all mutation experiments each treatment was in duplicate
except for positive controls where single cultures only were used.
Vehicle and positive control treatments were included throughout,
but since some less common vehicles were used, untreated controls
were included in many experiments to conﬁrm no adverse effects
from the vehicle.
 For 3 h treatments with most of the test substances (cobalt
dihydroxide, cobalt metal powder, cobalt monoxide, cobalt ox-
alate, lithium cobalt dioxide, cobalt oxide hydroxide, cobalt
sulphate and cobalt sulphide), 107 cells were suspended in
17.0 mL of RPMI 5. For cultures prepared in this way, treatment
consisted of adding 2 mL vehicle or test chemical solution (or
0.2 mL positive control solution plus 1.8 mL vehicle), together
with S9 mix or 150 mM KCl, to give a ﬁnal volume of 20 mL. For
the remaining substances (except extract of cobalt metal pow-
der, described below), at least 107 cells were suspended in
18.9 mL of RPMI 5, or in 18.8 mL RPMI 5 for tricobalt tetraoxide,
cobalt 2-ethyl hexanoate and for positive controls, in a series of
sterile disposable 50 mL centrifuge tubes. For all treatments of
cultures prepared in this way, 0.1 mL vehicle or test chemical
solution (or 0.2mL tricobalt tetraoxide, cobalt 2-ethyl hexanoate
or positive control solution) was added. S9 mix or 150 mM KCl
(1.0 mL per culture) was added for treatments in the presence
and absence of metabolic activation, respectively, giving a ﬁnal
treatment volume of 20 mL.
 For 24 h treatments in the absence of S9, at least 4  106 cells in
a volume of 19.9mL RPMI 10 (19.8mL for positive controls) were
used. The cell suspensions were placed in a series of appropriate
sterile disposable containers which were gassed with 5% CO2 in
air. For all treatments of cultures prepared in this way 0.1 mL of
vehicle or test chemical solution (or 0.2 mL of positive control
solution) was added giving a ﬁnal treatment volume of 20 mL.
For some test substances (cobalt monoxide, cobalt sulphate and
cobalt sulphide) 4  106 cells were suspended in 18.0 mL of
RPMI 10. Treatment consisted of adding 2 mL vehicle or test
chemical solution (or 0.2 mL positive control solution plus
1.8 mL vehicle) to give a ﬁnal volume of 20 mL.
The treatments with the extract of cobalt metal powder were
different:
 For the 3 h treatments, at least 107 cells in a volume of 3 mL
RPMI 5 were placed in a series of sterile disposable 50 mL
centrifuge tubes. Then 16 mL vehicle (RPMI 5) or supernatant
from extraction as described above (0.2 mL positive control
solution plus 15.8 mL vehicle) was added. S9 mix or 150 mM KCl
(1.0 mL per culture) was added to give a ﬁnal volume of 20 mL.
 For the 24 h treatment in the absence of S9, at least 4  106 cells
in a volume of 4 mL RPMI 5 were placed in a series of sterile
disposable 75 cm2 tissue culture ﬂasks. Then 16 mL vehicle
(RPMI 5) or supernatant from extraction as described above (or
0.2 mL positive control solution plus 15.8 mL vehicle) was
added. Thus the ﬁnal volume was 20 mL.
After 3 h incubation at 37 C with gentle agitation (short
treatments), or after 24 h static incubation (long treatments), cul-
tures were centrifuged (200 g) for 5 min, washed and resuspended
in 20 mL RPMI 10. Cell densities were determined using a Coulter
counter and the concentrations adjusted to 2  105 cells/mL. Forassessment of survival, samples from these cultures were diluted to
8 cells/mL. Using a multichannel pipette, 0.2 mL of each of these
diluted cultures was placed into each well of 2 96-well microtitre
plates (192 wells, averaging 1.6 cells/well). The plates were incu-
bated at 37 C in a humidiﬁed incubator gassed with 5% CO2 in air
for 7 days. Wells containing viable clones were identiﬁed by eye
using background illumination and counted.
For the expression of Hprt mutations, post-treatment cultures
that had been adjusted to 2  105 cells/mL were maintained in
ﬂasks for a period of 7 days. Sub-culturing was performed as
required with the aim of not exceeding 1 106 cells/mL and, where
possible, retaining at least 6  106 cells/ﬂask. From observations on
recovery and growth of the cultures during the expression period,
appropriate cultures were selected to be plated for viability and
6TG resistance.
To determine viability at the end of the expression period, cell
densities in the selected cultures were determined using a Coulter
counter and adjusted to give 1  105 cells/mL. Samples from these
were further diluted in RPMI 20 (similar to RPMI 10 but with 20%
heat-inactivated horse serum and without pluronic) to 8 cells/mL.
Using a multichannel pipette, 0.2 mL of each diluted culture was
placed into each well of 2 96-well microtitre plates (192 wells
averaging 1.6 cells/well). The plates were incubated at 37 C in a
humidiﬁed incubator gassed with 5% CO2 in air for 8 days. Wells
containing viable clones were identiﬁed by eye using background
illumination and counted.
To select for mutation at the end of the expression period, 6 TG
(1.5 mg/mL) was diluted 100-fold into the 1  105 cells/mL cultures
to give a ﬁnal concentration of 15 mg/mL. Using a multichannel
pipette, 0.2 mL of each suspension was placed into each well of
4 96-well microtitre plates (384wells at 2 104 cells/well). Plates
were incubated at 37 C in a humidiﬁed incubator gassed with 5%
CO2 in air for 12e13 days and wells containing clones were iden-
tiﬁed as above and counted.
Cloning (plating) efﬁciency and mutant frequency were calcu-
lated in the same way as for Tk mutants (Mei et al., 2014). Relative
survival was used to determine cytotoxicity and was calculated by
comparing plating efﬁciencies in test and control cultures thus:
%RS ¼
h
PEðtestÞ
.
PEðcontrolÞ
i
 100
To take into account any loss of cells during the 3 or 24 h
treatment period, percentage relative survival values for each
concentration of test article were adjusted as follows:
Adjusted % RS ¼ % RS Post treatment cell concentration in treated culture
Post treatment cell concentration in vehicle control
Statistical analysis of mutant frequencies was carried out ac-
cording to Robinson et al. (1990). The control log mutant frequency
(LMF) was compared with the LMF from each treatment concen-
tration and the data were checked for a linear trend in mutant
frequency with test chemical treatment. These tests require the
calculation of the heterogeneity factor to obtain a modiﬁed esti-
mate of variance. The LMF for each treatment was compared with
control using Dunnett's test (one-sided). Linear trend was assessed
by weighted rank sum analysis and the level of signiﬁcance was
determined by chi-squared (one-sided) analysis.
A chemical was considered to be mutagenic in this assay if:
1. The mutant frequency at one or more concentrations was
signiﬁcantly greater than that of the negative control (p  0.05).
2. There was a signiﬁcant concentration-relationship as indicated
by the linear trend analysis (p  0.05).
3. The effects described above were reproducible.
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relative to vehicle controls was also taken into account, and in
general a 3-fold increase was considered biologically signiﬁcant.
Results that only partially satisﬁed the assessment criteria
described above or did not achieve biological signiﬁcance, were
considered on a case-by-case basis. Positive responses seen only at
high levels of cytotoxicity required careful interpretation when
assessing their biological relevance. Extreme caution was exercised
with positive results obtained at levels of RS lower than 10%.
3.5. Chromosomal aberration (CA) tests in mammalian cells
Cobalt acetyl acetonatewas suspended in tetrahydrofuran and
tested for CA induction in cultures of human lymphocytes. To
prepare each culture, 0.5 mL of heparinised whole blood from 2
healthy donors was added to 5 mL of RPMI 1640 medium con-
taining 20% foetal calf serum, L-glutamine (2 mM), penicillin
(100 U/mL), streptomycin (100 mg/mL) and phytohaemagglutinin
(PHA: a mitogen to stimulate lymphocyte division). The cultures
were then placed in an incubator at 37 C for 48 h, when treatment
was begun. Two independent experiments were performed, and in
each case cells were treated with cobalt acetyl acetonate for 3 h in
the absence or presence of S9, and harvested 20 h after the start of
treatment, corresponding to approximately 1.5 cell cycles. One and
a half hours before harvest, each culture was treated with a col-
cemid solution (10 mg/mL) to block cells at the metaphase-stage of
mitosis. Harvested cells were gently swollen by hypotonic treat-
ment (KCl, 0.075M), ﬁxed in amethanol/acetic acidmixture (3/1; v/
v), spread on glass slides and stained with Giemsa. All the slides
were coded, so that the scorer was unaware of the treatment group
of the slide under evaluation (“blind” scoring).
Positive control chemicals were MMC at 3 mg/mL in the absence
of S9, and CPA at 12.5 or 25 mg/mL for treatments in the presence of
S9.
At least 5 concentrations of cobalt acetyl acetonate were tested,
in duplicate, in each part of the study. Although added to the cul-
tures as a suspension in tetrahydrofuran, no precipitate was seen at
the end of treatment. Cytotoxicity was evaluated by mitotic index
(number of cells in mitosis/1000 cells examined). Where possible,
100 metaphases with 44e46 chromosomes were analysed for CA
from each replicate culture (200 metaphases/dose level) from the 3
highest concentrations producing acceptable levels of cytotoxicity
(target at least 50% mitotic inhibition).
For each test concentration and for each harvest time, the fre-
quency of cells with structural CA (excluding gaps) in treated cul-
tures was compared to that of the vehicle control cultures. If
necessary, the results were analysed using the c2 test, in which
p¼ 0.05 was used as the lowest level of signiﬁcance. A reproducible
and statistically signiﬁcant increase in the frequency of cells with
structural CA for at least one of the dose-levels was considered as a
positive result. Reference to historical data or other considerations
of biological relevance, was also taken into account in the evalua-
tion of the ﬁndings.
Cobalt resinatewas dissolved in tetrahydrofuran and tested for
CA induction in cultures of human lymphocytes according to a
protocol similar to that used for cobalt acetyl acetonate. However,
in the second experiment in the absence of S9 mix, cells were
exposed continuously to the test or control items until harvest,
whereas in the presence of S9 mix, cells were exposed for 3 h and
then rinsed. In both cases cells were harvested 20 and 44 h after the
beginning of treatment, corresponding to approximately 1.5
normal cell cycles and 24 h later, respectively. In the third conﬁr-
matory experiment, lymphocyte cultures were exposed to cobalt
resinate in the presence of S9 mix and harvested 20 h after the start
of treatment. Harvesting and slide preparationwere the same as forcobalt acetyl acetonate.
Positive control chemicals wereMMC at 3 mg/mL (3 h treatment)
or 0.2 mg/mL (20 or 44 h treatment) in the absence of S9, and CPA at
12.5 or 25 mg/mL for treatments in the presence of S9.
At least 5 concentrations of cobalt resinate were tested, in
duplicate, in each part of the study. A slight to marked precipitate
was seen at the end of treatment at concentrations of 37.5 mg/mL
and above. Cytotoxicity, scoring of CA and evaluation of results
were the same as for cobalt acetyl acetonate.
Another CA study was performed on V79 cells treated with
cobalt oxyhydroxide. V79 cells were obtained from the American
Type Culture Collection (ATCC CCL-93) and checked for myco-
plasma contamination before stocks were prepared and stored
frozen in liquid nitrogen. Thawed cultures were set up in 75 cm2
ﬂasks (5  105 cells per ﬂask in 15 mL minimal essential medium
containing 10% foetal calf serum) at 37 C in an atmosphere of 5%
CO2 in air, and subcultured every 3e4 days. For the experiments,
cells were seeded into Quadriperm dishes containing microscope
slides (at least 2 chambers per dish and test group). Into each
chamber 1  104e5  104 cells were seeded dependent on prep-
aration time. Two days after seeding, the cells were treated either in
serum-free medium (short treatments) or in medium containing
10% foetal calf serum.
Cobalt oxyhydroxide was dissolved in cell culture medium prior
to treatment, and all treatments, including solvent and positive
controls (EMS in the absence of S9 and CPA in the presence of S9)
were in duplicate. Two independent experiments were performed.
In the ﬁrst experiment cells were treated with cobalt oxyhydroxide
for 4 h in the absence or presence of S9, and harvested 20 h after the
start of treatment. In the second experiment, cells were again
treated for 4 h in the presence of S9 and harvested at 20 h, but in the
absence of S9 treatment was continuous for 20 h until harvest.
Cytotoxicity was measured both by mitotic index (based on
1000 cells scored) and by cell density (mean of cell counts from 20
visual ﬁelds at 400x magniﬁcation). The concentrations chosen for
analysis were based on mitotic index (MI), which declined with
treatment concentration more steeply than cell density. Thus, top
concentrations were scored at which MI was reduced by >50%, as
required by current OECD guidelines, but in some cases exceeded
60%. Precipitation was present at all concentrations of cobalt oxy-
hydroxide tested.
Cells were arrested in metaphase by addition of Colcemid
(0.2 mg/mL for the ﬁnal 2.5 h) and the cells were gently swollen on
the slides with 0.4% KCl for 20 min at 37 C. Cells were ﬁxed with
methanol/glacial acetic acid (3:1, v/v), and stained with Giemsa.
Slides were coded before analysis. Only cells with 22 ± 1 chromo-
somes were scored, and 100 cells per replicate (200 cells per con-
centration) were scored for CA. No statistical analysis was
performed. CA frequencies were judged as biologically signiﬁcant
based on reference to historical negative control ranges.
3.6. Studies on production of reactive oxygen species (ROS) and
induction of oxidative damage
As an in vitro model system relevant for the assessment of
damage to the lungs, A549 lung epithelial cells were used for in-
vestigations on ROS production and induction of oxidative DNA
damage by cobalt octoate compared with the inorganic, water
soluble cobalt compound cobalt sulphate heptahydrate as a pos-
itive control for high cobalt solubility and cobalt-dependent bio-
logical effects. Cells were obtained from the German Collection of
Microorganisms and Cell Cultures (DSMZ, 38124 Braunschweig,
Germany). The cell lot used was tested and found free of myco-
plasma contamination.
Before cell exposure cobalt octoate and cobalt sulphate
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solution, pH 7.4) or artiﬁcial alveolar ﬂuid (AAF, pH 7.4) to simulate
dissolution in the physiological lung environment. The salts used
for preparation of the artiﬁcial ﬂuids were purchased from different
providers in highest purity. Gamble's solution was composed of
magnesium chloride hexahydrate (0.2033 g/L), sodium chloride
(6.0193 g/L), potassium chloride (0.2982 g/L), dibasic sodium
phosphate (0.1420 g/L), sodium sulphate (0.0710 g/L), calcium
chloride dihydrate (0.3676 g/L), sodium acetate trihydrate
(0.9526 g/L), sodium bicarbonate (2.6043 g/L), sodium citrate
dihydrate (0.0970 g/L). Salts were successively dissolved under
stirring in 950 mL of double distilled water in the given order.
Finally pH was adjusted to pH 7.4 using HCl/NaOH and the solution
was ﬁlled up to 1 L. AAF was prepared like the Gamble's solution,
but contained, in addition, phosphatidylcholine (0.1000 g/L; Sig-
maeAldrich, 82024 Taufkirchen, Germany). For supplementation of
phosphatidylcholine the solution was heated to approximately
60 C after adjustment of pH, and phosphatidylcholine was added
under stirring. Finally pH was checked and AAF was ﬁltered to
remove any potentially undissolved material.
Directly before use cobalt octoate and cobalt sulphate hepta-
hydrate were pulverised with a pestle and mortar under liquid
nitrogen. From each cobalt compound 0.2 gwere then suspended in
10 mL of either artiﬁcial interstitial ﬂuid (Gamble's solution) or
artiﬁcial alveolar ﬂuid (AAF) to simulate dissolution in physiological
environments. Solutions were subsequently shaken for 48 h. After
48 h the extracts were divided into two equal aliquots. One of the
aliquots was ﬁrst ﬁltered through a 0.45 mm ﬁlter, followed by
ﬁltration through a 0.1 mm ﬁlter, to remove any solids. The second
aliquot was used without a ﬁltration step. To evaluate the impact of
particles on the biological activity of cobalt octoate both the ﬁltered
(soluble) and unﬁltered fractions were used for measurement of
ROS production (see 3.6.1) and for the hOGG1-modiﬁed comet
assay (see 3.6.2). The concentrations given in the results section
(50e800 mg/mL) refer to the originally weighted substance mass of
0.2 g/10 mL with subsequent dilutions. The concentrations don't
represent real substance concentration in the different fractions
after extraction and ﬁltration. The extraction and ﬁltration proce-
dure was repeated for each of the various runs of the different
experiments. In each run, each chemical was extracted once.
Aliquots of two different fractions were also used for determi-
nation of cobalt solubility of the two test chemicals in every
experiment after shaking for 48 h in Gamble's or AAF. The soluble
cobalt content was analysed by ICP-MS using the prepared samples
after recommended dilution with water. For all solvent ratios and
ﬁnal sample volumes, blank solutions were also prepared. Cobalt
ion concentrations were ﬁnally expressed as mg cobalt per ml of the
extract.
3.6.1. Production of reactive oxygen species (ROS)
For ROS production, A549 cells were seeded into 96-well plates
(2  104 cells/well) and cultivated overnight. On the next day, the
medium was replaced by 100 mL of Hanks' Balanced Salt Solution
(HBSS, SigmaeAldrich, Germany) with 50 mM HDCF-DA and was
kept in the dark for one hour. Cells were then washed and exposed
to 100 mL chemical suspensions which were previously diluted in
HBSS to be able to achieve ﬁnal dilutions that spanned a range from
non-cytotoxic to slightly cytotoxic. Five concentrations (100, 200,
400, 600 and 800 mg/mL) of each preparation of cobalt octoate and
cobalt sulphate heptahydrate were tested. At least two replicate
experiments were performed with each preparation of the cobalt
compounds. The amount of generated DCF was determined after
4 h by measurement of ﬂuorescence intensity at 528 nm using
excitation at 485 nm (Molecular Devices). The mean values of
triplicates were recorded.Cytotoxicity was measured after 4 h by Hoechst and WST-1
assay (described below). Cell cultures containing only HBSS and
no chemicals were used as a reference control. For the Hoechst
cytotoxicity assay, cells were ﬁxed and incubated with staining
reagent (Hoechst 33,258$10 mg/mL) for 10 min at room tempera-
ture. Cells were washed and ﬂuorescence was analysed using a
microtiter plate reader (Molecular Devices, Spectramax Gemini) at
352 nm (excitation) and 461 nm (emission). The WST-1 assay
(Roche, Mannheim, Germany) was used as another test for cyto-
toxicity. Cells were therefore incubatedwith andwithout chemicals
as described above. Supernatant was removed and cells were
incubated with 100 mLWST-1 solution per well as described by the
manufacturer. The absorbance was determined at 420e480 nm
with a reference wavelength of 690 nm.
All data were calculated as means ±SD. Statistical analyses were
performed by the non-parametric Dunnett's test (Software:
GraphPad Prism 4, version 4.03). Differences between exposed
samples and controls were considered as statistically signiﬁcant at
the level of p < 0.05.
3.6.2. Detection of DNA strand breaks and oxidative DNA lesions
using the hOGG1-modiﬁed comet assay
To investigate induction of DNA-strand breaks and oxidative
DNA lesions cobalt octoate and cobalt sulphate heptahydrate
were prepared in Gamble's solution and AAF and cobalt solubility
was measured as described above. The extracts prepared at con-
centrations of 20 mg/mL were ﬁnally diluted with HBSS to the
desired concentrations, i.e. 50, 200 and 800 mg/mL for cobalt
octoate, and 800 mg/mL for the inorganic, water soluble positive
control cobalt compound, cobalt sulphate heptahydrate. Both ex-
tracts, in Gamble's and AAF, were tested in the ﬁrst set of comet
assay experiments. Two independent additional experiments were
performed with AAF as extraction ﬂuid. In the ﬁrst set of experi-
ments particle size distribution was determined for the particle
fractions of cobalt octoate. In the comet assay experiments cobalt
octoate was compared with HBSS buffer as negative control,
aluminium oxide particles (Al2O3, 200 mg/cm2, 4 h) as particulate
negative control, with cobalt sulphate heptahydrate as cobalt
positive control, with ethyl methanesulfonate (EMS, 0.75 mL/mL,
1 h) as clastogenic positive control and potassium bromate (KBrO3,
1 mM, 4 h) as positive control chemical that induces oxidative DNA
lesions, in particular 8-hydroxy-2-deoxy-guanosine (8-OH-dG).
Notably, in the comet assay oxidative DNA-base modiﬁcations can
only be detected if lesion-speciﬁc repair enzymes like human 8-
hydroxyguanine DNA-glycosylase 1 (hOGG1) are used.
For the comet assay experiments A549 cells were seeded in
DMEM culture medium (Biochrom GmbH, Berlin, Germany), sup-
plemented with 10% FCS and antibiotics (gentamicin, ﬁnal con-
centration 5 mg/mL in DMEM, Life Technologies GmbH Invitrogen,
Darmstadt, Germany) onto 12-well plates (1.75  105 cells per
well). Before incubation with the test chemical or the reference
items, the cells were grown overnight at 37 C in a humidiﬁed at-
mosphere of 95% air and 5% CO2 using an incubator. Cytotoxicity
was determined by cell counting using an enhanced Neubauer
counting chamber.
DNA-strand breaks and oxidative DNA lesions (8-OH-dG) were
analysed in A549 cells after 4 h of incubation (1 h only for the
positive control EMS) with 1 mL of the different extracts, using the
hOGG1-modiﬁed alkaline comet assay, originally described by
Smith et al. (2006), based on the alkaline version of the comet assay
(Singh et al., 1988; Tice et al., 2000). In brief, after detachment from
the culture surface, two aliquots of A549 cells per treatment con-
ditionwere centrifuged for 5 min at 900 rpm (Heraeus Biofuge® 15,
Thermo Scientiﬁc, Germany), re-suspended in pre-heated 0.75%
low melting agarose (peqlab, Erlangen, Germany), applied to
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and lysed overnight at 4 C to liberate the DNA. One of the two
slides per treatment condition was subsequently incubated for
12 min with 0.16 U/mL of hOGG1 (New England Biolabs, Ontario,
Canada) to detect oxidative DNA-damage. The other slide received
enzyme buffer only. In both cases, DNA-unwinding and electro-
phoresis were done on ice, in 4 C cold electrophoresis buffer
(300mMNaOH,1mMEDTA, pH > 13). DNAwas ﬁnally stainedwith
ethidium bromide and analysed using the Comet Assay III software
from Perceptive Instruments (Steeple Bumpstead, Haverhill, UK).
All methodological steps, following cell detachment, were per-
formed under red light to avoid unspeciﬁc DNA damage due to UV-
irradiation. As themain endpoint the tail intensity (TI) of 100 nuclei
per slide (if available) and treatment (with or without hOGG1 in-
cubation) were determined per experiment. The TI is a direct
measure for the amount of damaged DNA that can be standardised
among various studies. An increase in TI on the hOGG1-treated
slides, as compared to the slides treated with enzyme buffer only,
was indicative for the occurrence of the oxidative DNA base lesion
8-OH-dG. The comet assay analyses were all performed in a blinded
manner, without knowledge of the identity of the test chemicals.
The comet assay datawere calculated asmeans ±SD. Student's t-
test was used to evaluate differences between the negative controls
and the treated cells or the slides without and with hOGG1-
treatment (unpaired and paired comparisons, respectively).
As the particle size is crucial for uptake of particles by cells and
subsequent intracellular ROS-liberation by cobalt ions in the cyto-
plasm, the lysosomal compartment, or for very small particles even
in the nucleus, particle size distribution in the incubation media
(particle fraction) was determined for cobalt octoate in both
Gamble's and AAF and correlated with data on DNA damage and
cytotoxicity. For determination of the particle size distribution the
particle fractions of cobalt octoate in Gamble's solution and AAF
were used directly after extraction and were diluted with HBSS to
get suspensions of assumed 50 mg material per 10 mL of HBSS. The
diluted suspensions (about 10 mL) were sucked onto Nucleopore®
ﬁlters (diameter 25mm). Filters were then rinsed oncewith 5mL of
water to remove salt crystals from the extraction solutions and
from HBSS which can disturb analysis. Part of the ﬁlter was then
mounted on an aluminium stub and prepared for scanning electron
microscopy (SEM) analysis. Determination of particle size distri-
bution was performed at 2000 x (AAF) to 3000 magniﬁcation
(Gamble's) using a scanning electron microscope (SEM) and an FE-
SEM Supra 55 with image analysis software Scandium (Zeiss Co.).
The samples were checked ﬁrst by energy dispersive X-ray spec-
troscopy (EDX) in the SEM for their cobalt content. As particles are
not spheres, the length (highest diameter) and diameter (extension
perpendicular to the length) of about 200 particles per extract were
then measured. Finally, the geometric diameter Dg was calculated
as mean value of length and diameter for each particle and mass
weighting was used for analysis of the diameter distribution. The
resulting diameters of the cobalt octoate samples were presented
as geometric means with standard deviations. All data were
recorded electronically and evaluated using the SAS software
package (Version SAS Institute, Cary, NC, USA, Release 9.1 on
Windows XP Computer).
3.7. Bone marrow micronucleus (MN) tests in vivo
Cobalt resinate and cobalt acetyl acetonate were tested for
induction of MN in mouse bone marrow cells. The studies were
conducted in compliance with the following Animal Health regu-
lation: Council Directive No. 86/609/EEC of 24th November 1986 on
the harmonisation of laws, regulations or administrative provisions
relating to the protection of animals used for experimental or otherscientiﬁc purposes. Swiss Ico: OF1 (IOPS Caw) mice, 6 weeks old,
were obtained from Charles River Laboratories, l'Arbresle, France.
They were housed in cages in a roommaintaining a temperature of
22 ± 2 C, with relative humidity of 30e70% and a 12 h light/dark
cycle. Ventilation achieved at least 12 cycles/hour of ﬁltered non-
recycled fresh air. All animals had free access to SsniffR/M-H pel-
leted maintenance diet (SSNIFF Spezialdi€aten GmbH, Soest, Ger-
many), and drinking water ﬁltered by an FG Millipore membrane
(0.22m) was provided ad libitum. Mice were acclimatised for at least
5 days prior to treatment.
Both substances were suspended in 0.5% MC and administered
orally by gavage to groups of 5 male and 5 female mice on 2 occa-
sions, 24 h apart (additional animals were included in the top dose
groups to allow for any unexpected mortalities). Range-ﬁnding
studies were conducted to select the dose levels for the main
studies. In each case doses above the selected top dose induced
mortalities, and clinical signs (hypoactivity, piloerection) were
observed at the selected top dose, which was therefore considered
the maximum tolerated dose (MTD). The MTD plus 2 other dose
levels were used for the main studies. The doses given were:
 Cobalt resinate to males at 375, 750 and 1500 mg/kg/day
 Cobalt resinate to females at 187.5, 375 and 750 mg/kg/day
 Cobalt acetyl acetonate to males and females at 125, 250 and
500 mg/kg/day.
Negative control groups were dosed with the vehicle (0.5% MC)
on 2 occasions. Positive control animals were treated with 50 mg/
kg cyclophosphamide (CPA) on a single occasion. All mice were
killed by asphyxiation with CO2 24 h after the second or only dose.
The femurs were removed and the bone marrow was ﬂushed out
using foetal calf serum. After centrifugation, the supernatant was
removed and the sedimented cells were resuspended by shaking. A
drop of this cell suspension was placed and spread on a slide. The
slides were air-dried, stained with Giemsa, and coded before
scoring “blind”. For each animal, 2000 polychromatic erythrocytes
(PCE) were counted to determine the MN frequency, and a total of
1000 erythrocytes were counted to determine the ratio of PCE to
normochromatic erythrocytes (NCE).
The MN data were analysed for homogeneity within each group
using the heterogeneity chi-square test. When there was no sig-
niﬁcant within-group heterogeneity, the frequencies of MN PCE in
each treated group were compared with those in the concurrent
vehicle control group by using a 2 2 contingency table to deter-
mine the c2 value. When there was signiﬁcant within-group het-
erogeneity, then that group was compared with the control group
using a non-parametric analysis, theManneWhitney test. Student's
t-test was used for the PCE/NCE ratio comparison. Probability
values of p  0.05 were considered as signiﬁcant.
Blood samples were taken from small groups of animals 2 h after
the second treatment but could not be analysed for plasma levels of
each test chemical due to technical problems.
3.8. Bone marrow chromosomal aberration (CA) test in vivo
A non-GLP bone marrow chromosomal aberration (CA) study
was performed with cobalt sulphate, cobalt monoxide and tri-
cobalt tetraoxide following oral administration to rats. The study
protocol was approved by the Charles River institutional animal
care and use committee. The test facility is regularly assessed and
certiﬁed by the Canadian Council on Animal Care (CCAC). Weanling
SpragueeDawley SD® (Hsd:SD®) albino outbred rats were obtained
from Harlan, USA, and were approximately 14 days old upon
dispatch. A minimum acclimation period of 5 days was allowed
between animal receipt and the start of treatment. Animals were
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treatment groups. Animals in poor health or at the extremes of the
body weight range were not assigned to groups.
Animals remained with their respective dams throughout
acclimation and exposure periods. Each dam and litter were housed
(groups of 13 pups in the single dose phase study and 9 to 11 pups
in the multi-dose phase study) on corn-cob bedding (Bed’O-Cob®)
in solid-bottomed cages equipped with an automatic watering
valve. Each dam andweanling animal was uniquely identiﬁed using
the AIMS® tail tattoo system. During the study, temperature was
maintained at 22 ± 3 C, relative humidity was 50 ± 20%, and the
light cycle was 12 h light and 12 h dark (except during designated
procedures). All animals had free access to a standard certiﬁed
pelleted commercial laboratory diet (PMI Certiﬁed Rodent 5002,
PMI Nutrition International Inc.) except during designated pro-
cedures. Maximum allowable concentrations of contaminants in
the diet were controlled and routinely analysed by the manufac-
turers. Municipal tap water, suitable for human consumption, was
freely available except during designated procedures.
The study included a preliminary single dose phase using
groups of 2 male and 2 female rats, which received the following
doses (dose volume 10 mL/kg):
 Cobalt sulphate e 80, 160 and 320 mg/kg
 Cobalt monoxide e 100, 300 and 1000 mg/kg
 Tricobalt tetraoxide e 500, 1000 and 2000 mg/kg.
The vehicle control was aqueous 1% MC. An additional vehicle
control group was included in this phase to conﬁrm that adminis-
tration of colchicine did not cause any substantial increase in
micronuclei or other nuclear anomalies (see later). This phase was
intended primarily to determine acute toxicity and to provide
preliminary genotoxicity information. The results were used to help
determine the maximum tolerated doses, and to select additional
dose levels and tissues for examination in the subsequent multi-
dose phase, which was designed in accordance with appropriate
guidelines for in vivo genotoxicity tests. In the multi-dose phase,
groups of 5 male and 5 female rats were treated daily with the
vehicle control or each cobalt compound for up to 5 consecutive
days. The dose levels were:
 Cobalt sulphate e 100, 300 and 1000 mg/kg/day (equivalent to
cobalt doses of 21, 63 and 210 mg/kg/day)
 Cobalt monoxidee 200, 600 and 2000mg/kg/day (equivalent to
cobalt doses of 157, 472 and 1573 mg/kg/day)
 Tricobalt tetraoxidee 200, 600 and 2000mg/kg/day (equivalent
to cobalt doses of 47, 141 and 470 mg/kg/day).
Positive control animals in both phases of the experiment were
treated with a single low dose of CPA or DMH. All animals were
dosed orally by intra-gastric gavage and were sampled 16 h after
the last, or only, treatment, having been injected, where appro-
priate, with colchicine (4 mg/kg) 1 h earlier.
The bone marrow from both femurs of each animal was pooled/
eluted in 5 mL Hanks' Balance Salts Solution by aspiration with a
syringe and needle. The resulting cell suspensions were centrifuged
at ca. 1000 rpm for 5 min. The pellets were resuspended in 10 mL
aqueous 0.075M (hypotonic) KCl and incubated for approximately
12 min at ca. 37 C. The cells were ﬁxed (methanol: acetic acid, 3:1),
centrifuged, washed with 3 changes of neat ﬁxative, and resus-
pended in a small volume of ﬁxative. The ﬁxed cells were dropped
onto clean slides in a humid atmosphere and air-dried before
staining. At least two slides were prepared from each animal. Slides
werewashedwith 3 changes of puriﬁedwater, stainedwith 10% v/v
Giemsa for 15 min, rinsed, air-dried and mounted with coverslips.Metaphases containing between 40 and 44 chromosomes were
accepted for scoring and 100 cells/animal scored for CA. Mitotic
index was determined from counting 1000 cells/animal. Histolog-
ical sections of appropriate organs (potential sites of genotoxicity
and carcinogenicity) were quantitatively examined for nuclear
anomalies (NA) produced as a result of apoptosis. These NA were
described as follows:
 “Nuclear anomalies/aberrations are bizarre nuclear forms easily
recognised in histological sections; they are formed by
condensation and degradation of the nucleus as a result of single
cell necrosis. Single cell necrosis (also referred to as apoptosis or
cytotoxicity) is characteristically seen in tissues containing
dividing cells following treatment of animals or people with
DNA damaging agents including radiation and cytotoxic drugs.
No good methods exist for examining chromosome breakage in
solid tissues. Therefore, examination for nuclear anomalies
represents a relatively sensitive and practical alternative
method of detection of DNA damage in these tissues following
exposure to a chemical. Note that micronuclei also form in the
same tissues following treatment with DNA damaging agents
and are classiﬁed as nuclear anomalies; they generally form as a
result of chromosome damage rather than cell necrosis.”
Increases in NA can be a useful screen for genotoxic damage in
solid tissues of whole animals where conventional cytogenetic
examination is impractical, although the possibility remains that
NA may be induced by non-genotoxic mechanisms. Mitotic index
was also recorded.
The toxicity of the cobalt compounds was much more pro-
nounced following multiple administrations so that, in the case of
sulphate and the monoxide, many animals could not be dosed for
the planned 5 days, due to severity of clinical signs and mortalities.
Therefore, some animals were sampled earlier than planned and
group sizes were sometimes substantially reduced, which may
have impacted the sensitivity of the study. Only the low dose sul-
phate group (100 mg/kg/day) survived until the end of the 5-day
dosing, and no CA data could be obtained from the mid or high
dose group animals. Also, no CA datawere obtained from females in
the high dose monoxide group. Thus, although the initial design of
the study complied with OECD guidelines, deaths and early sacri-
ﬁces compromised the compliance. Tricobalt tetraoxide was less
toxic and animals survived dosing with 200, 600 or 2000 mg/kg/
day for 5 days. However, the vehicle and positive control groups
were all dosed and sampled as planned.
Due to the limited group size, no formal statistical analysis was
performed on results from the single dose experiment. The mitotic
indices (MI), incidences of CA, and NA (corrected for number of cells
examined if variable) for the multi-dose phase were subjected to
non-parametric statistical analysis using StatXact (Cytel Inc, Mass.).
Exact two-sided p-values were calculated for MI, and one-sided
values for other parameters using permutation tests (Gibbons,
1985; Agresti et al., 1990) based on absolute values and rank dose
level with the individual animal being considered as the unit of
variance. Comparison of different dose levels was not made
because, for the sulphate and the monoxide, the animals in each
group were not treated for the same period. MIs for animals not
treated with colchicine were excluded from the analysis.
3.9. Spermatogonial chromosomal aberration (CA) test in vivo
Cobalt dichloride hexahydrate was investigated for induction
of CA in spermatogonial cells of male SpragueeDawley CD rats
obtained from Charles River Laboratories Germany GmbH. The rats
were housed, fed, and handled as all other laboratory animals in
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health check approximately one week before commencement of
treatment, the animals were weighed and randomly allocated to
the test groups. All animals were healthy at the start of the study,
and on the ﬁrst day of dosing animals were 35 days old and
weighed 140.5e164.1 g. Commercial Ssniff® R/M-H V1530 diet
(Ssniff Spezialdi€aten GmbH, 59494 Soest, Germany) and drinking
water were provided ad libitum.
Fresh preparations of cobalt chloride dissolved in water were
made each day and administered orally by gavage once daily for 28
days. Dose levels that were initially selected, based on prior
knowledge, were 3, 10, 30, 100 and 300 mg/kg/day. However, since
deaths occurred at both 100 and 300 mg/kg/day, the maximum
tolerated dose was deemed to be 30 mg/kg/day. Data were there-
fore obtained from animals dosed with cobalt chloride at 3, 10 and
30 mg/kg/day for 28 days. The vehicle control group received water
daily by gavage. No concurrent positive control group was included
in this study, but the laboratory had obtained consistent signiﬁcant
positive responses with mitomycin C.
Animals were sacriﬁced 24 h after the last treatment. Three
hours prior to sampling, the animals received 4 mg colchicine/kg
b.w. i.p. The animals were sacriﬁced by ether. After having removed
the tunica albuginea, the seminiferous tubules of both testicles
were exposed to hypotonic 1% sodium citrate solution for 20 min.
Afterwards, still in toto, the seminiferous tubules were ﬁxed in
freshly prepared methanol/glacial acetic acid (3 þ 1) ﬁxative and
the samples were left overnight (about 16 h) at low temperature
(0e4 C). In order to prepare the slides, the samples were centri-
fuged and the ﬁxative was completely removed with a Pasteur
pipette. The pellet was gently resuspended by adding 60% acetic
acid. Approx. 50 mL of each cell suspension was dropped onto pre-
warmed slides at 48 C and spreads were made. The air-dried cells
were stained with 10% Giemsa (in buffered phosphate solution, pH
7.2) for 45 min. Afterwards the slides were mounted. At least two
slides were prepared per animal.
Analysis of CA was performed on all 3 cobalt chloride dose
groups, and on vehicle (water) controls. Slides for evaluation were
blind coded before microscopic analysis and examined at a
magniﬁcation of 1000 (Planapochromat 100/1.25). The mitotic
index was determined by counting the number of metaphases per
1000 cells in each cell preparation. The frequencies of structural CA
(chromosome- and chromatid type) were determined from 200
well-spread metaphases per animal. Since ﬁxation procedures
often result in breakage of some metaphases, with a concomitant
loss of chromosomes, only cells with 2n± 2 centromeres were
scored. Cells with an incomplete number of centromeres or insuf-
ﬁcient spreading were not used for analysis.
Statistical evaluation was carried out by comparing frequencies
of aberrant cells in treated groups with the vehicle controls, using a
chi-square test corrected for continuity according to Yates, as rec-
ommended by Lovell et al. (1989).
4. Results
4.1. Ames tests
4.1.1. Single strain tests
The results of the tests on cobalt metal in strain TA98, cobalt
chloride in TA97a and cobalt sulphate in TA100 are summarised in
Table 1.
Some slight differences in toxicity and precipitation were seen
across the 3 laboratories, and are not easy to explain, but this made
no impact on the robustness of the studies. The differences noted
and their effects on choice of concentrations can be summarised as
follows: All 3 laboratories obtained numbers of revertants/plate in
negative control cultures that were normal, except for 2 ex-
periments in Laboratory 3 (Table 1B) where the revertant counts
for TA97a were in one case considerably lower and in another
considerably higher than the historical control range, and the
experiments rejected. However, each laboratory demonstrated
clear positive responses with the positive control chemicals
(data not shown).
 For cobalt metal, which was suspended in DMSO by each lab-
oratory prior to addition to the plates, Flügge (2013a) observed
insoluble material at all concentrations tested, Laboratory 3
observed precipitation at concentrations of 1000 mg/plate and
above, whereas Laboratory 2 did not observe any precipitation.
Each laboratory saw toxic effects which led to slightly different
selection of top concentration, as can be seen from the table.
 For cobalt chloride, all 3 laboratories observed some toxic ef-
fects (reduced background lawn of growth or reduced numbers
of revertants) in some experiments at the higher concentrations,
although in the studies from Laboratory 3 these observations
were not consistent between repeat experiments, and in one of
the experiments using plate incorporation the laboratory
observed widespread bacterial colony growth in the absence of
S9 which necessitated manual counting. Laboratory 3 also
observed some precipitation at 2500 mg/plate and above in all
experiments. This led to slightly different selection of top con-
centrations, as can be seen from the table.
 For cobalt sulphate, each laboratory selected a top concentra-
tion of 5000 mg/plate, but whereas Flügge (2013c) and Labora-
tory 3 observed some precipitate but no toxicity at this
concentration, Laboratory 2 did not see any precipitate but did
note some toxicity.
Although Laboratory 3 had some inconsistent results and
needed to repeat some experiments, there were no clear or
reproducible positive responses even for this laboratory alone.
When the responses seen in the other 2 laboratories are considered,
where maximum increases in revertant numbers were always low
and there was no evidence of dose responses (peak revertant
counts occurred randomly across the concentration range), it is
clear that these 3 substances have not produced the mutagenic
responses seen with these strains in published papers (see Intro-
duction) either in the absence or presence of S9, using either plate
incorporation or pre-incubation methodology.
4.1.2. Five strain tests
Cobalt acetyl acetonate (Supplementary Table 1) induced slight
toxicity (slightly reduced revertant counts) at the top concentration
in some strains. Cobalt resinate (Supplementary Table 2) was not
toxic at the concentrations tested but did produce precipitate at
concentrations of 250 mg/plate and above. Negative control rever-
tant frequencies for all strains in both experiments were normal,
and were signiﬁcantly increased by positive control treatments.
Cobalt resinate induced small but biologically signiﬁcant (i.e. >2-
fold) increases in TA98 revertants at the lowest and highest con-
centrations in the absence of S9 in Experiment 1. The increase at the
top concentration could be considered to be dose-related, but the
responses were not reproduced under the same conditions in
Experiment 2. They may be due to chance or technical error and are
not considered biologically relevant. All other strains treated with
cobalt resinate, both in the absence and presence of S9, exhibited
revertant frequencies that were similar to controls and there were
no biologically signiﬁcant or dose-related increases. All strains
treated with cobalt acetyl acetonate, both in the absence and
presence of S9, exhibited revertant frequencies that were similar to
controls and there were no biologically signiﬁcant (maximum
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related increases. Therefore it is concluded that neither cobalt
resinate nor cobalt acetyl acetonate induced reverse mutations in
Ames bacteria.
4.2. Mammalian cell gene mutation tests
4.2.1. Mouse lymphoma Tk mutation tests
For both studies described below, negative control mutant fre-
quencies fell within acceptable ranges, and the positive control
chemicals induced signiﬁcant increases in mutant frequency.
The results for cobalt resinate are summarised in
Supplementary Table 3. It produced precipitate at the end of
treatment at the top 2 or 3 concentrations, which could have been
problematical, as it is difﬁcult to separate the suspended cells from
the precipitate by centrifugation at the end of treatment, but ap-
pears not to have interfered with the study. In the absence of S9 the
top concentration induced approximately 50% toxicity (reduction in
relative total growth, RTG) in both 3 and 24 h treatments. In the
presence of S9 the top concentration was less toxic and induced
only 15e25% reduction in RTG. Although target levels of toxicity
(>80%) were not reached, the inclusion of several precipitatingTable 1
Summary of results with single Ames strains.
A. Cobalt metal powder in TA98
Experiment
and condition
Flügge (2013a) Laboratory 2
Maximum
concentration
tested (mg/plate)
Maximum fold increase in
revertants (at concentration,
mg/plate)
Maximum
concentration
tested (mg/plate)
Expt. 1, S9 1000PL 1.4 (31.6) 5000*PL
Expt. 1, þS9 1000PL 1.3 (31.6) 5000*PL
Expt. 2, S9 1000PR 1.3 (3.16) 5000*PL
Expt. 2, þS9 1000PR 1.0 (100) 5000*PR
* Extensive toxicity seen. PL ¼ plate incorporation; PR ¼ pre-incubation.
B. Cobalt chloride in TA97a
Experiment
and condition
Flügge (2013b) Laboratory 2
Maximum
concentration
tested (mg/plate)
Maximum fold increase in
revertants (at concentration,
mg/plate)
Maximum
concentration
tested (mg/plate)
Expt. 1, S9 3160*PL 1.1 (100) 5000*PL
Expt. 1, þS9 3160*PL 1.0 (31.6) 5000*PL
Expt. 2, S9 3160*PR 1.0 (1000) 5000*PL
Expt. 2, þS9 3160*PR 1.0 (316) 5000*PR
Expt. 3, S9
Expt. 3, þS9
Expt. 4, S9
Expt. 4, þS9
* Slight toxicity seen. PL ¼ plate incorporation; PR ¼ pre-incubation.
a Experiments were considered invalid because solvent control counts were outside h
C. Cobalt sulphate in TA100
Experiment
and condition
Flügge (2013c) Laboratory 2
Maximum
concentration
tested (mg/plate)
Maximum fold increase in
revertants (at concentration,
mg/plate)
Maximum
concentration
tested (mg/plate)
Expt. 1, S9 5000PL 1.0 (1000) 5000*PL
Expt. 1, þS9 5000PL 1.2 (100) 5000*PL
Expt. 2, S9 5000PR 1.1 (5000) 5000*PL
Expt. 2, þS9 5000PR 1.1 (5000) 5000*PR
Expt. 3, S9
Expt. 4, S9
Expt. 4, þS9
Expt. 5, S9
Expt. 5, þS9
* Slight toxicity seen. PL ¼ plate incorporation; PR ¼ pre-incubation.
Italics indicate results questionable due to “plateau” effect across all test concentrationconcentrations constitutes a valid assay. Mutant frequencies in all
treated cultures were very similar to concurrent controls, and there
were no increases that approached a biologically signiﬁcant level,
i.e. did not approach the Global Evaluation Factor (GEF) of þ126
mutants per 106 cells as recommended by Moore et al. (2006).
Therefore cobalt resinate did not induce Tk mutations in mouse
lymphoma cells in a robust test up to precipitating concentrations.
The results for cobalt acetyl acetonate are summarised in
Table 2.
It can be seen that increases in mutant frequency that exceeded
the GEF were induced in cultures treated in the absence of S9 in
both experiments. These increases were only seen at relatively high
levels of toxicity (reductions in RTG of 70% or more), and were not
dose-related in the second experiment, but the toxic effects were
not dose-related either. Biologically signiﬁcant increases in mutant
frequency were also seen in the ﬁrst experiment in the presence of
S9. The result at the top concentration (91.625 mg/mL) should be
ignored because excessive toxicity (>90%) was induced and arte-
facts can occur under such highly toxic conditions. A signiﬁcant
increasewas also seen at a lower level (36%) of toxicity, but this was
not clearly reproduced in the second experiment at similar con-
centrations and levels of toxicity e mutant frequencies did notLaboratory 3
Maximum fold increase in
revertants (at concentration,
mg/plate)
Maximum
concentration
tested (mg/plate)
Maximum fold increase in
revertants (at concentration,
mg/plate)
1.6 (158.1) 5000*PL 1.4 (333)
1.0 (158.1) 5000*PL 1.1 (333)
1.2 (156.3) 5000*PR 1.3 (33)
1.0 (625) 5000*PR 1.2 (333)
Laboratory 3
Maximum fold increase in
revertants (at concentration,
mg/plate)
Maximum
concentration
tested (mg/plate)
Maximum fold increase in
revertants (at concentration,
mg/plate)
1.0 (15.81) 5000*PL 2.7 (2500)a
1.2 (15.81) 5000PL 1.7 (2500)
1.0 (625) 5000*PR 1.6 (3750)
0.9 (312.5) 5000*PR 0.9 (5000)a
5000PL 1.5 (100)
5000*PL 0.8 (3)
5000*PR 1.1 (333)
5000*PR 0.9 (1)
istorical range.
Laboratory 3
Maximum fold increase in
revertants (at concentration,
mg/plate)
Maximum
concentration
tested (mg/plate)
Maximum fold increase in
revertants (at concentration,
mg/plate)
1.3 (5000) 5000PL 1.1 (333)
1.2 (1581) 5000PL 1.3 (1000)
1.1 (1250) 5000PR 2.1 (100 & 333)
1.2 (5000) 5000PR 1.4 (5000)
1000PR 2.0 (125)
5000PL 1.9 (5000)
5000PL 1.4 (2500)
5000PR 1.7 (2500)
5000PR 1.5 (5000)
s.
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cultures, both large and small colony mutants were induced, but
the predominant response was induction of small colony mutants,
indicative of a clastogenic (chromosome damaging) effect. There-
fore, cobalt acetyl acetonate did induce Tk mutations in mouse
lymphoma cells, particularly in the absence of S9, and the effect
was predominantly clastogenic.
4.2.2. Hprt mutation studies
In all studies negative control mutant frequencies (MF) were
within the historical range established by the laboratory, and pos-
itive control chemicals induced signiﬁcant increases inMF (data not
shown).
The results for the 7 salts/compounds and cobalt metal powder
tested only for 3 h in the absence and presence of S9 are sum-
marised as follows:
 Cobalt dihydroxide precipitated in culture medium and per-
sisted to the end of treatment at concentrations of 116.1 mg/mL
and higher. However, as shown in Supplementary Table 4, it was
toxic at much lower concentrations. It did not induce any sta-
tistically or biologically signiﬁcant increases in mutant fre-
quency (MF) when tested up to toxic concentrations in the
absence of S9. Statistically signiﬁcant increases in mutant fre-
quency (MF) were seen at 1 or 2 concentrations in the presence
of S9 in two out of three experiments, but the MF only exceeded
3x the historical control mean (8.34 per 106 cells, considered
biologically signiﬁcant) at 1 concentration in 1 experiment. Also,
a signiﬁcant dose-response trend was only seen in a different
experiment and was therefore not reproducible. The increased
MF are therefore of questionable biological relevance. Overall it
is concluded that cobalt dihydroxide did not induce biologically
relevant Hprtmutations when tested up to toxic concentrations
in the absence or presence of S9.
 The results for lithium cobalt dioxide are summarised in
Supplementary Table 5. It can be seen that in each part of the
study little or no toxicity was induced, but the top concentration
was limited by solubility. In none of the treated cultures were
the MFs statistically signiﬁcant when compared to concurrent
controls, no MFs exceeded 3x the historical control means
(9.42e12.36 mutants per 106 cells for the different treatment
conditions), and there were no dose-related trends. It is there-
fore concluded that lithium cobalt dioxide did not induce Hprt
mutations when tested to toxic concentrations in the absence or
presence of S9.
 The results for cobalt oxide hydroxide are summarised in
Supplementary Table 6. It can be seen that the top concentration
in each part of each experiment was limited by solubility and
induced little or no toxicity. MFs in all treated cultures were
similar to those in controls, not statistically different, did not
exceed 3x the historical control means (11.04e13.14mutants per
106 cells for the different treatment conditions), and there were
no dose-related trends. It is therefore concluded that cobalt
oxide hydroxide did not induce Hprt mutations when tested to
precipitating concentrations in the absence or presence of S9.
 Cobalt oxalate precipitated in culture medium and persisted to
the end of treatment at concentrations of 70 mg/mL and higher.
However, as discussed earlier and as can be seen from
Supplementary Table 7, it was toxic at this and lower concen-
trations, inducing >80% reduction in relative survival at the top
concentrations evaluated for mutations. It did not induce any
statistically or biologically signiﬁcant increases in MF when
tested up to toxic concentrations in the absence of S9. A statis-
tically signiﬁcant increase in MF was seen at 1 intermediate
concentration in the second experiment in the presence of S9,and did exceed 3x the historical control mean (8.19 mutants per
106 cells). However, the isolated increase inMFwas not seen at a
similar concentration and similar level of toxicity in the ﬁrst
experiment, and there was no dose-response. The increase in
MF is therefore of questionable biological relevance and prob-
ably due to chance. Overall it is concluded that cobalt oxalate did
not induce biologically relevant Hprt mutations when tested up
to toxic concentrations in the absence or presence of S9.
 As mentioned earlier, cobalt metal powder clearly precipitated
in culture medium and undissolved cobalt metal powder was
present at many lower concentrations. As can be seen from
Table 3 it was toxic at low concentrations, particularly in the
absence of S9. Themarked variability in the toxic responses in the
presence of S9 between the different experiments may be a
reﬂection of the fact that undissolved cobalt metal powder was
present, andmay have exerted toxic effects on the cells due to its
physical presence. It didnot induce any statistically or biologically
signiﬁcant increases inMFwhen testedup to toxic concentrations
in the absence of S9, although a weak dose-response was seen in
the second experiment. Statistically signiﬁcant increases in MF
were seen at single intermediate concentrations in each of the
experiments in the presence of S9, and a dose-responsewas seen
in the second experiment. However, the MFs did not exceed 3x
historical control means (6.69 or 9.0 mutants per 106 cells for
treatments in the absence and presence of S9 respectively). A
third experiment was performed in the presence of S9 in order to
investigate these ﬁndings further. In this experiment, signiﬁcant
increases in MF were seen at 30 and 40 mg/mL accompanied by a
signiﬁcant dose-response. The MFs at these concentrations were
close to or exceeded 3x the historical control mean, and may
therefore be considered biologically relevant. Overall it is
concluded that cobalt metal powder did not induce biologically
relevantHprtmutationswhen testedup to toxic concentrations in
the absence of S9, but did induce weak, reproducible mutagenic
effects in the presence of S9. The inﬂuence of undissolved cobalt
metal powder on the toxic andmutagenic effects seen is unclear.
 The results for tricobalt tetraoxide are summarised in
Supplementary Table 8. It can be seen that the top concentration
in each experiment was the lowest producing persistent pre-
cipitate through the treatment period, but did not induce sig-
niﬁcant toxicity (maximum 34% reduction in relative survival).
Although some MFs exceeded concurrent negative control
values, none were statistically signiﬁcant, did not exceed 3x
historical control means (9.6e11.79 mutants per 106 cells for the
different treatment conditions), and there were no dose-related
trends. It is therefore concluded that tricobalt tetraoxide did not
induce Hprt mutations when tested to precipitating concentra-
tions in the absence or presence of S9.
 The results for cobalt 2-ethyl hexanoate are summarised in
Supplementary Table 9. It can be seen that the top concentration
in each part of the study produced >80% reduction in relative
survival. Although some MFs exceeded concurrent control
values, none were statistically signiﬁcant, did not exceed 3x
historical control means (10.35e12.69 mutants per 106 cells for
the different treatment conditions), and there were no dose-
related trends. It is therefore concluded that cobalt 2-ethyl
hexanoate did not induce Hprt mutations when tested to toxic
concentrations in the absence or presence of S9.
The results for the 5 substances tested both for 3 h in the
absence and presence of S9, and for 24 h in the absence of S9, are
summarised as follows:
 The results for cobalt sulphate are summarised in
Supplementary Table 10. It can be seen that the top
Table 2
Mouse lymphoma Tk mutation results with cobalt acetyl acetonate.
Expt. S9 Treatment period (hrs) Conc. of cobalt acetyl acetonate (mg/mL) Mutant frequency (106) % Toxicity (reduction in RTG)
1 e 3 0 105 e
2.93 91 2
5.86 87 5
11.46 86 13
22.90 116 6
45.83 144 15
91.625 383 83
2 e 3 0 160 e
11.43 168 26
22.87 184 19
45.74 239 48
60.99 471 70
76.23 275 58
91.77 415 72
1 þ 3 0 139 e
2.93 135 e
5.86 119 e
11.46 94 e
22.90 132 2
45.83 307 36
91.625 1222a 98a
2 þ 3 0 107 e
11.43 73 e
22.87 96 17
45.74 113 20
60.99 185 40
76.23 222 52
91.77 222 62
Bold italics indicate biologically signiﬁcant responses (increase in mutant frequency exceeds GEF).
a Values are considered unreliable and should be rejected due to excessive (>90%) toxicity.
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in relative survival. Cobalt sulphate did not induce any statisti-
cally or biologically signiﬁcant increases in MF when tested up
to toxic concentrations in the absence of S9 using either 3 or
24 h treatments. Statistically signiﬁcant increases in MF were
seen at the 2 highest concentrations in the second experiment in
the presence of S9 leading to a dose-response, but the concur-
rent control MF was unusually low, and the MFs in the treated
cultures did not exceed 3x the historical control mean (8.7
mutants per 106 cells). Moreover, these increases inMFwere not
seen at even higher concentrations and similar levels of toxicity
in the ﬁrst experiment. The increases in MF are therefore of
questionable biological relevance. Overall it is concluded that
cobalt sulphate did not induce biologically relevant Hprt muta-
tions when tested up to toxic concentrations in the absence or
presence of S9, even when extended treatment periods were
used in the absence of S9.
 The results for cobalt sulphide are summarised in
Supplementary Table 11. It can be seen that for the 3 h treatments
the maximum concentration was 10 mM (922 mg/mL). However,
following 24 h treatment,>80% reduction in relative survival was
induced at 800 mg/mL. Although some MFs exceeded concurrent
control values, none were statistically signiﬁcant, did not exceed
3x historical control means (6.9, 7.8 and 6.06 mutants per
106 cells for 3 h in the absence and presence of S9, and 24 h in the
absence of S9, respectively), and there were no dose-related
trends. It is therefore concluded that cobalt sulphide did not
induce Hprt mutations when tested either to 10 mM or toxic
concentrations in the absence or presence of S9.
 Cobalt monoxide precipitated in culture medium and persisted
to the end of treatment at concentrations of 60e80 mg/mL and
higher. However, as mentioned previously and as can be seen
from Supplementary Table 12, it was toxic in this concentration
range particularly in the absence of S9. Although MFs wereincreased in some of the cultures treated in the presence of S9,
they did not exceed control MFs seen elsewhere in this series of
studies. A 3-fold increase in MF was seen at one of the inter-
mediate concentrations in the 24 h treatment protocol, but it
was not signiﬁcantly different from the concurrent control and
there was no dose response. In fact none of the MFs in any part
of the study, either in the absence or presence of S9, were sta-
tistically signiﬁcant when compared to concurrent controls, and
none exceeded 3x the historical control means (7.5e8 mutants
per 106 cells for the different treatment conditions) which
would be required for biological signiﬁcance. It is therefore
concluded that cobalt monoxide did not induce Hprt mutations
when tested to precipitating concentrations in the absence or
presence of S9.
 Cobalt borate neodecanoate precipitated in culture medium
and persisted to the end of treatment at concentrations of
100 mg/mL and higher. However, as can be seen from
Supplementary Table 13, it was toxic at lower concentrations,
inducing >80% reduction in relative survival at 2.75e3.0 mg/mL
in the absence of S9, and at 50e60 mg/mL in the presence of S9
following short (3 h) treatments. It was also toxic following 24 h
treatments, and the maximum concentration used was 2.0 mg/
mL, which induced 90% reduction in relative survival. Therefore
all concentrations evaluated for mutations were soluble. A sta-
tistically signiﬁcant increase in MF was seen at the highest
concentration in the second experiment with 3 h treatment in
the absence of S9, and it did exceed 3x the historical control
mean (6.72 mutants per 106 cells), although it did not exceed
control MFs observed elsewhere in this series of studies, and
there was no dose-response. Moreover, the isolated increase in
MF was not seen at similar or higher concentrations and similar
levels of toxicity in the ﬁrst experiment with 3 h treatment.
Dose-responses were seen in the ﬁrst experiment with 3 h
treatment in the absence of S9 and in both experiments with 3 h
Table 3
Hprt mutation data with cobalt metal powder.
Expt. S9 Treatment time (hr) Treatment (mg/mL) Mutant frequency (per 106 cells) Cytotoxicity (reduction in % relative survival)
1 e 3 0 2.66 0
1.172 2.38 5
2.344 1.31 11
4.688 1.44 2
9.375 2.10 22
18.75 0.95 59
37.5 4.70 92
1 þ 3 0 2.69 0
50 3.70 74
100 4.39 78
150 2.12 56
200 6.99 89
250 4.14 81
2* e 3 0 1.72 0
5 1.26 19
10 1.62 1
15 1.48 14
20 1.14 29
30 2.36 25
35 2.87 32
40 3.39 92
50 3.30 78
2** þ 3 0 1.60 0
10 1.11 4
20 0.82 0
40 5.75 53
60 3.65 97
3*** þ 3 0 2.28 0
5 3.73 9
10 4.71 24
30 9.46 68
40 8.82 84
Bold ﬁgures indicate statistically signiﬁcant from vehicle control (Dunnett's test, p < 0.05).
Asterisks indicate signiﬁcant linear trend in this data set (*p < 0.05; **p < 0.01; ***p < 0.001).
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enced by low negative control MFs, and, apart from the excep-
tion described earlier, none of the MFs in these treated cultures
were statistically signiﬁcant when compared to concurrent
controls. Following 24 h treatment in the absence of S9 all MFs
were similar to control and there were no signiﬁcant differences
or dose response. Overall it is concluded that cobalt borate
neodecanoate did not induce biologically relevant Hprt muta-
tions when tested up to toxic concentrations in the absence or
presence of S9.
 For the extract of cobalt metal powder Tyndall analysis
showed that no undissolved solid was found in the supernatant
after the 72 h extraction and centrifugation, and therefore the
preparation was suitable for testing.
As can be seen from the summary data in Table 4, at the top
concentrations of the extract tested, relative survival was
reduced to <20% under all treatment conditions, indicating that
divalent cobalt cations were liberated during the extraction
process and induced toxic effects in the cells. In Experiment 1
(3 h treatments in the absence and presence of S9 with top
concentrations of 290 and 320 mg/mL respectively) no statisti-
cally signiﬁcant increases in MF were observed following
treatment with extract at any concentration tested and there
were no signiﬁcant linear trends. In Experiment 2, statistically
signiﬁcant increases in MF, compared to the concurrent vehicle
controls, were observed at concentrations of 105 mg/mL in the
absence of S9 (24 h treatment) and 290 mg/mL in the presence of
S9 (3 h treatment). However, the mean MFs in these cultures
were only 4.99 and 6.21 mutants/106 viable cells. These fre-
quencies did not exceed 3x the historical control mean MFs
(5.61 and 6.78 mutants per 106 cells respectively) and weretherefore considered not to constitute a biologically relevant
positive response. Furthermore, although a statistically signiﬁ-
cant linear trend was seen in the absence of S9 (but not in the
presence of S9) in Experiment 2, there appeared to be no clear
concentration-related effects in the presence of S9 in Experi-
ment 2 and no evidence of reproducibility between Experi-
ments 1 and 2 in the absence or presence of S9. Overall, these
increases in MF were considered sporadic and of no biological
relevance. Thus, the weak responses seen with cobalt metal
powder in the earlier study were not reproduced with extracts
of the powder, when tested to toxic concentrations.
4.3. Chromosomal aberration (CA) tests in vitro
A summary of the key results for cobalt acetyl acetonate is
given in Table 5. Although some statistically signiﬁcant increases in
% cells with CA were seen at low and middle concentrations, fre-
quencies below 5% would probably not be considered biologically
signiﬁcant, although they do exceed the upper limits of the his-
torical control ranges, namely 2.5 and 3% in the absence and
presence of S9 respectively. At ﬁrst sight it appears that biologically
signiﬁcant induction of CA is only seen at concentrations of cobalt
acetyl acetonate inducing >50% toxicity. The second experiment in
the absence of S9 gave a most unusual toxicity response (not dose-
related) and therefore the reported 18%mitotic inhibition at 150 mg/
mL is probably not reliable, but higher concentrations could not be
scored as they were very cytotoxic. However, biologically signiﬁ-
cant increases in CA were clearly seen at modest levels of mitotic
inhibition in the second experiment in the presence of S9. There-
fore it does not seem likely that the increased levels of CA are an
indirect result of excessive toxicity.
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 There is a consistent pattern of increased CA frequencies in both
the presence and absence of S9
 The effects are reproducible across independent experiments
 The increased CA are not exclusively associated with high
(>50%) levels of cytotoxicity
it is concluded that cobalt acetyl acetonate did induce a bio-
logically meaningful clastogenic response in human lymphocytes
both in the absence and presence of S9.
A summaryof thekey results forcobalt resinate is given inTable6.
The data from this study are not easy to interpret, possibly
because of the impact of treating suspension cultures with
precipitating concentrations. The following inconsistencies arise:
 In Experiment 1 in the absence of S9 it is not clear why cyto-
toxicity increased through the precipitating range.
 In Experiment 2 with 20 h treatment in the absence of S9 there
is less (in fact no) toxicity at the same concentrations that
induced increasing toxicity after only 3 h treatment. Longer
treatments at the same concentration would be expected to be
more toxic. On the other hand, 44 h treatment in the absence of
S9 is much more toxic.
 In the 3 h treatment in the presence of S9 in Experiment 1 the
toxicity proﬁle exhibited a plateau across the precipitating range
(which would be expected), yet in Experiment 2 there was
neither a plateau nor a dose response, and in Experiment 3 there
was some evidence of a dose-related toxic response. On the
other hand, after 41 h recovery, signiﬁcant toxicity was induced.
Some of the inconsistencies in toxicity probably reﬂect the dif-
ﬁculties in removing precipitate from suspension cultures
following 3 h treatments. However, the inconsistencies following
continuous treatments are not readily explained.
The small increase in CA frequency (4.5%) at the lowest con-
centration in Experiment 1 in the absence of S9 is probably due to
chance and not biologically signiﬁcant. The increases in CA fre-
quency in Experiment 1 in the presence of S9 were not reproduced
in Experiment 2 (but then neither was the toxicity); however they
were reproduced in Experiment 3 where toxicity similar to that
seen in Experiment 1 was induced. Overall it can be concluded that
cobalt resinate does induce CA in the presence of S9, although the
impact of cytotoxicity on these responses is unclear because of the
confounding factor of precipitation.
The results of the CA assay with cobalt oxyhydroxide in V79
cells are summarised in Table 7.
According to the mitotic index measures, the top concentrations
induced at least 58% cytotoxicity, which is in the target range
speciﬁed in OECD guidelines. However, in some cases >60% mitotic
inhibition was induced, and results at such high levels of cytotox-
icity need to be interpreted with caution. In fact, the latest revision
to OECD guideline 473 (OECD, 2014) states that care should be
taken even when interpreting positive results found only at the
upper end of the target cytotoxicity range. The only treatment that
induced a biologically signiﬁcant increase in CA frequency at less
than 50% reduction in mitotic index was the 20 h continuous
treatment at 200 mg/mL in the absence of S9. All other increases
were associated with at least 59% reduction in mitotic index.
Current guidelines for genotoxicity testing in mammalian cells
recommend that only 1 concentration should be included at which
precipitate is present at the end of treatment. This is to demon-
strate that an acceptable upper concentration was evaluated but
without creating artefacts. The impact of precipitation at every
concentration tested in this study is unclear. As mentioned earlier,it is curious howmitotic index and cell density continued to decline
with increasing concentrations of cobalt oxyhydroxide through the
insoluble range. Precipitate can “blanket” cells growing in mono-
layer, and inhibit nutrient uptake and gas exchange, leading to
physiological stress and cytotoxicity. This would be a particular
problem in cultures treated for long periods of time (e.g. the 20 h
treatments in the absence of S9). Thus, it is highly likely that the
presence of persistent precipitate in the 20 h treatments resulted in
physiological stress leading to both cytotoxic and genotoxic effects.
All of the observed increases in CA frequency, including at 200 mg/
mL in the 20 h treatment, may well be an indirect consequence of
such physiological stress.
In addition, V79 cells have been shown to be particularly sus-
ceptible to giving positive results with substances that are not
genotoxic in vivo or carcinogenice so-called “misleading” or “false”
positive results (Fowler et al., 2011). Hamster cells such as V79 that
are p53-deﬁcient, genomically altered, and potentially genomically
unstable, are much more likely to express genotoxic changes
resulting from effects on non-DNA targets, oxidative damage, or
metabolic overload than p53-competent, normal diploid cells.
Thus, the biological relevance of the CA results with cobalt oxy-
hydroxide is unclear.
4.4. Tests for oxidative damage
4.4.1. Production of reactive oxygen species (ROS)
From the analysis of cobalt in the extractionmedia, it was shown
that signiﬁcant concentrations of cobalt ions could be recovered
(around 40e50 mg/mL for cobalt octoate and around 60e70 mg/mL
for cobalt sulphate heptahydrate in Gamble's solution), and were
therefore bioavailable to the cells. These concentrations were stable
over 24 h.
Following a 4 h exposure of A549 cells to both AAF and Gamble's
solution extracts of cobalt octoate, DCFH was oxidised resulting in
a strong increase of DCF ﬂuorescence (up to 949% in AAF and 725%
in Gamble's solution, see Fig.1). Metabolic activity and DNA content
were reduced after incubation with high concentrations of cobalt
octoate (400 and 800 mg/mL, particulate fractions). Here, ROS for-
mation was already observed at non-cytotoxic concentrations
(<400 mg/mL) of cobalt octoate. Both ﬁltered and unﬁltered extracts
of cobalt octoate induced ROS formation, indicating that the cobalt
released from the particulate fraction gave rise to the same ROS
levels as medium directly prepared with the corresponding tran-
sition metal ion (Fig. 1).
Exposure of A549 cells to highly soluble cobalt sulphate hep-
tahydrate extracted in either AAF or Gamble's solution also resul-
ted in increases in DCF ﬂuorescence after 4 h (increase up to 1090%
in AAF and 859% in Gamble's solution, Fig. 2). Again both ﬁltered
and unﬁltered extracts of cobalt sulphate heptahydrate induced
ROS formation. Both cobalt compounds are therefore highly com-
parable for their effects on ROS formation. However, ROS produc-
tion by cobalt octoate was associated with marked cytotoxicity
(measured both by Hoechst and WST-1), whereas for cobalt sul-
phate ROS production was not associated with cytotoxicity (cf.
Figs. 1 and 2).
4.4.2. hOGG1-modiﬁed comet assay
To enable a better understanding and comparison of the bio-
logical effects of cobalt octoate and the inorganic, water soluble
cobalt sulphate heptahydrate, as a positive reference item, cobalt
solubility was determined in all soluble fractions. Cobalt octoate
and cobalt sulphate heptahydrate exhibited different cobalt mass
contents of 17 and 21%, and thus a theoretical cobalt net weight per
ml at extraction start of 3.40 and 4.19 mg/mL, respectively. In AAF,
cobalt sulphate heptahydrate exhibited the higher cobalt solubility,
Table 4
Hprt mutation data with an extract of cobalt metal powder.
Expt. S9 Treatment time (hr) Treatment (mg of cobalt used for extraction/mL) Mutant frequency (per 106 cells) Cytotoxicity (reduction in % relative survival)
1 e 3 0 4.68 0
120 1.16 0
160 3.34 0
200 4.14 4
230 5.20 43
260 3.81 66
290 3.57 90
1 þ 3 0 1.34 0
120 2.73 8
160 2.98 2
200 1.64 0
230 3.38 48
260 1.83 40
290 2.62 77
320 1.66 89
2*** e 24 0 1.26 0
40 0.79 20
60 1.71 25
75 4.29 31
90 2.55 33
105 4.99 65
120 3.57 47
135 3.88 72
150 4.02 83
2 þ 3 0 2.10 0
100 1.99 0
150 2.29 7
200 1.82 23
230 1.90 27
260 1.59 53
290 6.21 73
320 4.80 76
350 2.57 85
Bold ﬁgures indicate statistically signiﬁcant from vehicle control (Dunnett's test, p < 0.05).
Asterisks indicate signiﬁcant linear trend in this data set (***p < 0.001).
Table 5
Chromosomal aberration (CA) results for cobalt acetyl acetonate in human lymphocytes.
Expt. S9 Treat þ Recovery (hr) Conc. of cobalt acetyl acetonate (mg/mL) % cells with CA (excl. gaps) % toxicity (reduction in mitotic index)
1 e 3 þ 17 0 0 0
34 3.5 31
68 4.7 47
136 18.0 56
2 e 3 þ 17 0 0 0
75 3.5 0
100 3.5 43
150 12.0 18
1 þ 3 þ 17 0 0.5 0
17 4.5 16
34 4.5 31
68 32.0 68
2 þ 3 þ 17 0 0.5 0
50 8.0 35
75 12.0 46
100 26.0 64
Bold ﬁgures indicate statistical signiﬁcance. Bold italics indicate both statistical and clear biological signiﬁcance.
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(¼70.8% of the theoretical cobalt net weight; n ¼ 6 independent
fractions), as compared to 2.06 ± 0.065 mg/mL (¼60.7 ± 1.90% of
the theoretical cobalt net weight; n ¼ 3 independent fractions) for
cobalt octoate. Extraction with Gamble's led to comparable results
(data not shown).
In addition, cobalt octoate particle size distribution was
determined in the unﬁltered incubation media. By using energy
dispersive X-ray spectroscopy in SEM, most of the particles present
were shown to contain no cobalt, which was in line with the high
cobalt solubility of cobalt octoate in AAF of about 61%. The analysedfractions were composed of particles of a wide size range (data not
shown) with in part very small, respirable particles, up to larger
agglomerates. But, irrespective of the extraction ﬂuid, the particles
in the cobalt octoate unﬁltered fractions exhibited geometric mean
values (weighting by mass) which exceeded respirable dimensions.
Geometric mean values of the cobalt octoate fractions in Gamble's
solution (7.54 ± 1.95 mm) were more close to respirable dimensions
than the cobalt octoate fractions in AAF (10.26 ± 1.79 mm).
Induction of DNA strand breaks and oxidative DNA lesions by
the AAF-extracted cobalt compounds, as determined using the
hOGG1-modiﬁed comet assay, are shown in Fig. 3. Negative
Table 6
Chromosomal aberration (CA) results for cobalt resinate in human lymphocytes.
Expt. S9 Treat þ Recovery (hr) Conc. of cobalt resinate (mg/mL) % cells with CA (excl. gaps) % toxicity (reduction in mitotic index)
1 e 3 þ 17 0 1.0 0
75P 4.5 39
150P 2.0 49
300P 2.0 61
2 e 20 þ 0 0 0.5 0
75P 0.5 0
150P 2.0 0
300P 1.5 0
2 e 44 þ 0 0 1.5 0
18.8 2.0 61
1 þ 3 þ 17 0 1.5 0
75P 6.5 44
150P 18.0 44
300P 16.0 49
2 þ 3 þ 17 0 0 0
75P 0.5 15
150P 1.5 21
300P 2.5 0
2 þ 3 þ 41 0 0.5 0
75P 3.0 59
3 þ 3 þ 17 0 0.5 0
37.5 4.0 47
75P 7.3 34
150P 8.7 69
P ¼ precipitate observed at harvest.
Bold ﬁgures indicate statistical signiﬁcance. Bold italics indicate both statistical and clear biological signiﬁcance.
Table 7
CA results for cobalt oxyhydroxide in V79 cells.
Expt. S9 Treat þ Recovery
(hr)
Conc. of cobalt oxyhydroxide
(mg/mL)
% cells with CA
(excl. gaps)
% toxicity (reduction
in mitotic index)
% toxicity (reduction
in cell density)
1 e 4 þ 16 0 1.5 e e
100P 1.5 10 10
200P 3.0 45 15
300P 2.0 67a 11
2 e 20 þ 0 0 2.5 e e
100P 2.5 18 9
200P 7.0 16 22
400P 7.0 61a 18
500P 8.0 70a 12
1 þ 4 þ 16 0 2.0 e e
250P 3.5 21 23
500P 1.0 16 2
1000P 1.5 58 15
2 þ 4 þ 16 0 3.5 e e
600P 1.5 21 25
800P 3.5 13 24
1000P 2.7 34 24
1200P 3.7 60a 34
1500P 8.0 59 42
Bold italics indicate clear CA frequencies that exceed historical control range.
P ¼ precipitate observed at harvest.
a Cytotoxicity reaches or exceeds the current recommended upper limit of 60%.
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mean tail intensity (TI) of 0.86 ± 0.081%. The clastogenic positive
control EMS, a direct alkylating compound, induced a sufﬁciently
high, signiﬁcant increase in TI (mean TI: 6.59 ± 1.382%, p  0.01),
indicating that the comet assay method was performed correctly
and that the cells were sensitive towards directly DNA-damaging
substances. In cells treated with KBrO3 there was no increase in
TI without hOGG1 incubation (mean TI: 0.76 ± 0.070%) and thus no
direct DNA-strand break induction. In contrast, after incubation
with hOGG1, a marked statistically signiﬁcant increase in TI after
KBrO3 exposure was noted, if compared to the respective slides
without enzyme treatment (mean TI: 31.72 ± 8.641%, p  0.05).
Human OGG1-induced increase in TI indicated sufﬁcient activity ofthe positive control and the hOGG1 enzyme batch used and also
sensitivity of the cell system towards oxidative DNA-base lesions.
Cobalt octoate, after extraction in AAF, induced a signiﬁcant
increase in mean TI, compared to the HBSS control, which was
statistically signiﬁcant at the highest concentration of the soluble
fraction (mean TI at 800 mg/mL: 7.95± 1.959%, p 0.01) and the two
highest concentrations of the unﬁltered fraction (mean TI at
200 mg/mL: 2.68 ± 0.497%, p  0.01; mean TI at 800 mg/mL:
9.73 ± 1.966%, p  0.001). At all concentrations tested, mean TI was
further enhanced in the presence of hOGG1, indicating induction of
oxidative DNA-base lesions. Induction of oxidative DNA-base le-
sions was signiﬁcant at the highest concentration used (800 mg/mL)
for both the ﬁltered (soluble) and the unﬁltered fractions, with
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(p  0.01) and 16.70 ± 3.477% (p  0.05), respectively. The inor-
ganic, water soluble positive control cobalt sulphate heptahydrate
induced a signiﬁcant increase in TI by using both the ﬁltered (sol-
uble) (mean TI: 6.41 ± 3.389%, p  0.01) and unﬁltered fractions
(mean TI: 5.32 ± 1.537%, p  0.01), which was further enhanced in
the presence of hOGG1 (mean TI soluble fraction: 11.54 ± 6.438%;
mean TI unﬁltered fraction: 11.93 ± 6.064%), indicating oxidative
damage. Despite some differences in cytotoxicity (see below) the TI
values were not statistically different for the soluble and the
unﬁltered fraction, indicating that mainly cobalt solubility and the
cobalt cations are important determinants of the observed DNA
damaging effect and that the observed particles seemed to be of
minor relevance.
In pre-experiments with the positive control cobalt sulphate
heptahydrate, extracted in Gamble's, very high variability was
observed for TI values of the unﬁltered fractions. For this reason,
the main experiments were performed with AAF extracts only,
because of better reproducibility. Nevertheless there was one initial
experiment with direct comparison of AAF and Gamble's extracts
from cobalt octoate and cobalt sulphate heptahydrate. This exper-
iment indicated similar results, but with a tendency towards
slightly higher TI values for the Gamble's extracts.
In parallel to the hOGG1-modiﬁed comet assay experiments
with AAF extracts of cobalt sulphate heptahydrate and cobalt
octoate, manual cell counting was performed to estimate cytotox-
icity (see Fig. 4). The positive control cobalt sulphate heptahydrate
(800 mg/mL) clearly reduced mean cell counts in A549 cell cultures.
This was detected for both the soluble (33% reduction) and the
unﬁltered fraction (63% reduction, p  0.05). Thereby, higher
cytotoxicity of the unﬁltered fraction might indicate an additional,
particle-like effect. The soluble fractions also exhibited a cytotoxic
potential with reductions in cell number by 37 (50 mg/mL), 65A
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Fig. 1. Oxidation of DCFH to ﬂuorescent DCF in A549 cells after 4 h exposure to cobalt oc
exposure. Hoechst and Wst-1 ﬂuorescence intensity corresponding to DNA content and
chemical exposure. The chemical was extracted 48 h in AAF (A and B) or Gamble's solution
fraction (B and D). Data are given as mean ± standard error of mean. **p  0.01. WST-1 as(200 mg/mL), and 53% (800 mg/mL), respectively. For the unﬁltered
cobalt octoate extracts, signiﬁcant reduction in mean cell counts
(by 78%, p  0.05) was only observed for the highest concentration
used (800 mg/mL). At 200 mg/mL there was also marked cytotoxicity
in two out of three experiments, but the ﬁrst experiment demon-
strated unexpectedly high cell counts. Respective cytotoxicity of the
cobalt compounds was also observed for the extracts in Gamble's
(data not shown). In every case, marked induction of DNA-strand
breaks and oxidative DNA-base lesions seemed to coincide with
signiﬁcant reduction in cell number and thus cytotoxic activity of
the cobalt compounds.
4.5. Bone marrow micronucleus (MN) tests in vivo
The results of the mouse bone marrow MN tests are shown in
Tables 8 and 9 for cobalt acetyl acetonate and cobalt resinate
respectively. At the top dose (500 mg/kg/day) of cobalt acetyl
acetonate, two females out of eight were found dead 24 h following
the second treatment. At the top dose (1500 mg/kg/day) of cobalt
resinate, 1/5 males died just after the second treatment. In both
cases the dead animals were replaced by supplementary animals.
It can be seen that MN frequencies in vehicle control groups
were normal, and were signiﬁcantly increased by treatment with
the positive control, CPA. There was no evidence of bone marrow
toxicity (no signiﬁcant decrease in PCE:NCE ratio) in animals
treated with cobalt acetyl acetonate. However, there was a signif-
icant decrease in PCE:NCE ratio in the top dose males and females
treated with cobalt resinate. There were no signiﬁcant increases in
MN frequency in any of the groups treated with either cobalt
compound.
Blood samples were taken from treated animals 2 h after the
ﬁnal dose. Since cobalt resinate induced bone marrow toxicity, and
therefore demonstrated that systemic exposure to the chemicalB
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toate, given as ﬂuorescence intensity relative to reference cultures without chemical
metabolic activity, respectively, are also given relative to reference cultures without
(C and D) and exposed to cells as non-ﬁltered (NF) fraction (A and C) and ﬁltered (F)
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Fig. 2. Oxidation of DCFH to ﬂuorescent DCF in A549 cells after 4 h exposure to cobalt sulphate heptahydrate, given as ﬂuorescence intensity relative to reference cultures without
chemical exposure. Hoechst and WST-1 ﬂuorescence intensity corresponding to DNA content and metabolic activity, respectively, are also given relative to reference cultures
without chemical exposure. The chemical was extracted 48 h in AAF (A and B) or Gamble's solution (C and D) and exposed to cells as non-ﬁltered (NF) fraction (A and C) and ﬁltered
(F) fraction (B and D). Data are given as mean ± standard error of mean. *p < 0.05, **p  0.01. Wst-1 assay: n ¼ 3, Hoechst and ROS assay: n ¼ 4, each run was measured in triplicate.
Fig. 3. Induction of DNA-strand breaks and oxidative DNA-damage by cobalt octoate
and cobalt sulphate heptahydrate extracts in AAF. Human OGG1-modiﬁed comet assay.
A549 cells were incubated for 4 h with the unﬁltered or soluble fractions of the ex-
tracts in AAF (extraction 48 h at room temperature). Increase in TI without hOGG1-
incubation indicates occurrence of DNA-damage, in particular DNA single- and
double-strand breaks and alkali labile sites. Increase in TI with hOGG1-incubation, as
compared to the respective hOGG1-untreated slide, indicates oxidative DNA-damage.
Data represent mean values ±SD of three independent experiments. Signiﬁcantly
different from control cells (*) or from the respective hOGG1-untreated sample (#):
*/#p  0.05, **/##p  0.01, ***p  0.001, one-sided Student's t-test for unpaired
(*)/paired (#) values. EMS ¼ 0.75 mL/ml, 1 h; KBrO3 ¼ 1 mM, 4 h; CoSO4 ¼ 800 mg/mL,
4 h; CoOct ¼ 50, 200, or 800 mg/mL, 4 h; Al2O3 ¼ 200 mg/cm2, 4 h.
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concentrations. Cobalt acetyl acetonate did not induce bone
marrow toxicity, and therefore it would have been useful to analyse
the blood samples in order to demonstrate systemic exposure.
However, validation of the analytical method was prevented by
interferences with the biological matrix. Therefore analysis of the
plasma samples could not be undertaken. Thus, there was no direct
proof that cobalt acetyl acetonate was absorbed and achieved
systemic exposure. However, since:
 Notable clinical signs (half-closed eyes, hypoactivity, and
piloerection) were observed in both the range-ﬁnder and main
studies,
 Cobalt acetyl acetonate is more soluble than cobalt resinate,
which was clearly absorbed,
it is reasonable to conclude that cobalt acetyl acetonate was
absorbed and that the bone marrow was exposed.
Thus, neither cobalt acetyl acetonate nor cobalt resinate induced
MN in mouse bone marrow at doses up to the maximum tolerated.4.6. Bone marrow chromosomal aberration (CA) test in vivo
Although no mortalities occurred in the single dose phase of the
study with any of the cobalt compounds, mortalities did occur at
similar doses in the multi-dose phase (see Table 10).
Most chemicals show overt toxic effects (in terms of clinical
signs and mortalities) within a few hours of administration, at the
time when blood levels are highest. In comparison, the effects seen
later on histological examination and in the multi-dose phase were
consistent with delayed toxicity and indicated that dose levels for
cobalt sulphate and cobalt monoxidemaywell have exceeded the
maximum tolerable, where any genotoxic effects would need to be
D. Kirkland et al. / Regulatory Toxicology and Pharmacology 73 (2015) 311e338 333interpreted with caution. However, the exaggerated toxicity seen in
the multi-dose phase was likely due to cumulative toxic and
cytotoxic effects in the gastrointestinal tract and possible accu-
mulation of the chemicals in the animals. No mortalities occurred
in the vehicle, positive control or cobalt tetraoxide groups in the
multi-dose phase. Therefore, the appropriate numbers of animals
were sampled at the planned times and examined as planned. Two
animals sampled in the sulphate group, and one in the monoxide
group, were not dosed with colchicine due to the severity of the
clinical signs. Although two of these animals showed slightly
altered chromosome morphology compared with other animals in
the same groups, the incidence of structural and numerical aber-
rations in the bonemarrow and NA in other tissues was comparable
to other animals in the relevant groups, so these results were
included in the statistical analysis although mitotic index results
were necessarily excluded.
Mortalities in the multi-dose phase meant that mid-level sul-
phate and monoxide groups, as well as males in the high level
monoxide group, could not be sampled. In addition, the severity of
the clinical signs meant that other animals treated with sulphate
and monoxide were necessarily sampled after receiving fewer than
the 5 planned daily doses, although all animals received the min-
imum 2 doses necessary to comply with the guidelines. This
impacted the statistical power of the experiment, partly because
animals did not receive a comparable number of doses and (more
importantly) because the number of groups/animals sampled was
reduced below normally recommended levels. However, both sul-
phate andmonoxidewere evaluated at levels around themaximum
tolerated dose, where genotoxic effects (if seen) would be expected
to bemost pronounced. Although, theoretically, severe cytostatic or
cytotoxic effects in the bone marrow could result in a downturn in
response in the chromosome aberration test, neither of these were
evident in the present study.
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Fig. 4. Manual cell counts after incubation of A549 cells with cobalt octoate and cobalt
sulphate heptahydrate extracts in AAF. Cells were incubated for 4 h with the non-
ﬁltered or soluble fractions of the extracts in AAF (extraction 48 h at room tempera-
ture). Data represent mean values ±SD of three independent experiments. Signiﬁcantly
different from control cells: *p  0.05, two-sided Student's t-test for unpaired values.
EMS ¼ 0.75 mL/mL, 1 h; KBrO3 ¼ 1 mM, 4 h; CoSO4 ¼ 800 mg/mL, 4 h; CoOct ¼ 50, 200,
or 800 mg/mL, 4 h; Al2O3 ¼ 200 mg/cm2, 4 h.No treatment had any apparent effect on mitotic index in the
bone marrow. CA frequencies in vehicle control animals were
normal and were signiﬁcantly increased by treatment with the
positive control chemicals (data not shown). No notable increases
in the % cells with CAwere seen in the bonemarrowwith any of the
cobalt compound in this phase (data not shown).
No notable increases in NA were seen in the non-glandular
stomach, lungs or urinary bladder with any cobalt compound in
this phase (data not shown). Animals treated with cobalt sulphate
and cobalt monoxide showed dose-related increases in NA in all
regions of the intestine and, in the case of cobalt monoxide, in the
glandular stomach. Animals treated with tricobalt tetraoxide
showed weak or marginal increases in NA in the duodenum, ileum
and colon at the high dose level only (data not shown). Only cobalt
monoxide showed any clear evidence of inhibitingmitosis, with the
reduction in mitotic activity being perhaps most marked in the
rectum (data not shown).
(ii) CA and NA results for the multi-dose phase
The results of the bone marrow CA analyses are summarised in
Table 11. There was evidence of bone marrow toxicity with both
cobalt sulphate and cobalt monoxide, but mitotic index (MI)
increased at the low andmid-doses of cobalt tetraoxide. The reason
for this is not known. However, the effects on MI indicate that the
test chemicals were absorbed and exposure of the bone marrow
occurred.
It can be seen fromTable 11 that CA frequencies in vehicle control
animals were very low (0.2%). Animals treated with the positive
control CPA showed a signiﬁcant increase in % cells with CA. A
marginal increase in chromosome aberrations was obtained with
DMH in the single but not themultiple dose phase. These borderline
effects are consistent with similar borderline effects seen at some-
what higher doses in the rat andmouse bonemarrowmicronucleus
test with this compound (e.g. Hamada et al., 2001). It should be
noted that DMH is subject to ﬁrst pass metabolism therefore sub-
stantial systemic genotoxic effects were not expected with this
agent which was, however, expected to cause genotoxic effects in
the gut. The clear positive responses with CPA in both phases of the
study indicate the test system was sensitive to a known clastogen.
No increased CA frequencies were seen in animals treated with
tricobalt tetraoxide. Some increased CA frequencies were seen in
the top dose groups treated with cobalt sulphate and cobalt mon-
oxide. With such low CA frequencies in vehicle control animals in
this phase, the ﬁnding of 1.8% cellswith CA in the high dose sulphate
and monoxide groups of males could be indicative of a clastogenic
response. Mean CA frequencies of 1% had been seen historically in
control animals in the testing laboratory. However, frequencies of
0e2% are quite normal, and frequencies similar to this (1.5%) were
seen in control rats in the single-dose phase. Themarginal increases
could also have been an indirect result of the severity of clinical
signs at dose levels that proved to be above the MTD. Thus, these
slightly increased CA frequencies are probably the result of chance
variation and not biologically signiﬁcant; it is considered that none
of the cobalt salts induced CA in rat bonemarrowat high doses (at or
above the MTD) in the multi-dose phase.
The results for analysis of NA and effects on mitotic rate are
summarised in Table 12. Since the NA endpoint is not widely used,
there are no reference control data against which to judge the
frequencies of NA cells in vehicle control animals. Induction of NA
by CPAwas quite weak (only a slight effect in the rectum), but DMH
induced marked increases in NA in the rectum and slight increases
in the liver. Increases in NA in the large intestine and liver are
consistent with the known distribution and sites of carcinogenicity
for this compound. Marginal increases in NA were obtained in the
Table 8
Mouse bone marrow MN data for cobalt acetyl acetonate.
Group Doses (mg/kg/day) MN/1000 PCEa (group mean ±SD) PCE/NCE ratio (group mean ±SD)
Males
Vehicle e 0.7 ± 0.8 0.4 ± 0.1
Cobalt acetyl acetonate 125 0.8 ± 0.8 0.7 ± 0.2
250 1.4 ± 0.7 0.7 ± 0.2
500 1.6 ± 0.4 0.6 ± 0.1
CPAb 50 36.9 ± 11.6 0.7 ± 0.0
Females
Vehicle e 1.2 ± 0.3 1.0 ± 0.4
Cobalt acetyl acetonate 125 1.2 ± 0.8 0.8 ± 0.2
250 1.5 ± 0.9 0.7 ± 0.3
500 1.5 ± 0.6 0.6 ± 0.1
CPAb 50 30.0 ± 8.8 0.6 ± 0.1
Bold ﬁgures indicate statistically signiﬁcant (p < 0.05) from concurrent control.
a Based on 2000 PCE/animal scored.
b Positive control only administered once, 24 h prior to sacriﬁce.
Table 9
Mouse bone marrow MN data for cobalt resinate.
Group Doses (mg/kg/day) MN/1000 PCEa (group mean ±SD) PCE/NCE ratio (group mean ±SD)
Males
Vehicle e 0.6 ± 0.2 0.6 ± 0.1
Cobalt resinate 375 1.4 ± 1.1 0.7 ± 0.1
750 1.3 ± 1.1 0.4 ± 0.1
1500 0.9 ± 0.8 0.3 ± 0.1
CPAb 50 35.0 ± 17.8 0.8 ± 0.3
Females
Vehicle e 0.5 ± 0.4 0.9 ± 0.2
Cobalt resinate 187.5 0.9 ± 0.8 0.8 ± 0.1
375 1.1 ± 1.1 0.7 ± 0.2
750 0.9 ± 0.4 0.4 ± 0.2
CPAb 50 17.7 ± 3.2 0.7 ± 0.2
Bold ﬁgures indicate statistically signiﬁcant (p < 0.05) from concurrent control.
a Based on 2000 PCE/animal scored.
b Positive control only administered once, 24 h prior to sacriﬁce.
Table 10
Mortalities in the multi-dose phase of the in vivo chromosomal aberration/nuclear
anomaly study.
Treatment Dose (mg/kg/day) No. of dosing days Mortality
Males Females
Vehicle control 5 0/5 0/5
Cobalt sulphate 100 5 0/5 1/5
300 3 1/5 2/5
4 4/5 3/5
1000 2 1/5 0/5
Cobalt monoxide 200 3 1/5 2/5
4 4/5 3/5
600 2 0/5 0/5
2000 2 0/5 5/5
Cobalt tetraoxide 200 5 0/5 0/5
600 5 0/5 0/5
2000 5 0/5 0/5
CPA 10a 1 0/5 0/5
DMH 10a 1 0/5 0/5
a Single dose given on the day prior to euthanasia.
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agents. However, the mitotic rate (and therefore the number of
inducible anomalies) in this organ is low and variable. It is not
therefore clear whether the apparent increases in NA are due to
positive control treatments or due to normal variance. Again, since
there are no reference positive control data against which to
compare, it is unclear whether these positive control indicate that
the test system was appropriately sensitive, or not.Animals treated with cobalt sulphate showed clear increases in
NA in all regions of the intestine and, at the high dose only, a small
increase in anomalies in the liver. Slight increases in NA were also
seen in lung and bladder. However, as these tissues show a very low
and variable mitotic index, the apparent increases were not
considered conclusive. A slight increase in NA in the testes of ani-
mals tested with high dose cobalt sulphate could be due to indirect
toxic effects or normal variation, given the relatively low number of
animals involved.
Animals treatedwith cobalt monoxide showed clear increases in
NA in both regions of the gastrointestinal tract examined and in the
glandular stomach. Effects were seen to a lesser extent in the liver.
Animals treated with tricobalt tetraoxide showed marked or
slight increases in NA in the regions of the gut that were analysed,
but for the high dose group only.
Reductions in mitotic rate (consistent with a cytotoxic effect)
were generally evident in those tissues showing an increase in NA,
with the exception that an increase in mitotic rate in the glandular
stomach was obtained at the low dose of the sulphate. However,
reductions in mitotic rate were also seen in tissues where there
were no increases in NA. Reduced mitotic rates in the intestine of
animals treated with the sulphate and the monoxide were, in part,
explained by erosion of themucosal layer in these tissues, as well as
the direct cytotoxic effect.4.7. Spermatogonial chromosomal aberration (CA) test in vivo
No changes in behaviour, external appearance of the animals or
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cobalt chloride at any of the 3 dose levels. Although no obvious
clinical signs were observed at the doses used, some small but
statistically insigniﬁcant reductions in body weight were seen in
animals treated at 30 mg/kg/day (by 5.0% at day 8 and by 14.1% at
day 29). Reductions in absolute (25.0%) and relative liver weights
(12.3%) were seen in the 30 mg/kg/day group, but these were also
not statistically signiﬁcant. Since it would not have been possible to
use higher doses due to deaths at 100 and 300 mg/kg, the top dose
used in this study (30 mg/kg/day) is considered an acceptable
maximum tolerated dose.
The results of the CA analysis in spermatogonia are summarised
in Table 13. It can be seen that therewas no bonemarrow toxicity as
measured by mitotic index, and there were also no increases in the
frequency of CA. In the cobalt chloride groups all group mean
structural CA frequencies fell within the historical control range.
Also, there were no polyploid cells found from 1000 metaphases
scored in each of the groups. Although no concurrent positive
control was employed, the testing laboratory has consistently
observed signiﬁcantly increased CA frequencies (in the range
9e13%) in animals treated with mitomycin C. Although plasmawas
not analysed for presence of cobalt chloride, Nation et al. (1983)
demonstrated signiﬁcant exposure of multiple tissues after oral
dosing of cobalt chloride to rats.
5. Discussion
The published studies on the genotoxicity of soluble cobalt
compounds (such as cobalt chloride, cobalt sulphate) and cobalt
metal show some inconsistent results. Both positive and negative
ﬁndings have been reported for mutation in bacterial and
mammalian cells, and for induction of CA and MN both in vitro and
in vivo. The results from the new GLP studies also show some var-
iable responses, but with relatively clear evidence for chromosomal
aberrations in vitro, no clear evidence for chromosomal effects
in vivo and generally negative ﬁndings for gene mutation in vitro.
The published positive Ames results for cobalt chloride in strain
TA97a (Pagano and Zeiger, 1992), cobalt sulphate in TA100 (Zeiger
et al., 1992) and cobalt metal in TA98 (NTP, 2013) have not been
reproduced in three new GLP studies evaluating the relevant
strains. Also, cobalt resinate and cobalt acetyl acetonate were
negative in robust 5-strain Ames tests.
Earlier publications (Hartwig et al., 1990; Miyaki et al., 1979;
Kitahara et al., 1996) suggested soluble cobalt compounds couldTable 11
Bone marrow CA results for the multi-dose phase.
Treatment Dose (mg/kg/day) Relative MI
Vehicle control 0 100
Cobalt sulphate 100 97
1000 65
Cobalt monoxide 600 73
2000 39
Cobalt tetraoxide 200 139
600 154
2000 113
CPA 10* 117
DMH 10* 123
M ¼ male.
F ¼ female.
ND ¼ no data due to mortalities.
* Single dose given on day prior to euthanasia.
Bold ﬁgures indicate statistical signiﬁcance (p < 0.05).
Bold italics indicate values exceed laboratory historical control range.induce gene mutation in mammalian cells in vitro. However, the
predominantly negative results in recent GLPHprtmutation studies
with 10 different cobalt salts/compounds have not conﬁrmed this.
Cobalt chloride has not been reinvestigated for gene mutation in-
duction in mammalian cells, however negative Hprt mutation re-
sults with cobalt sulphate (which would equally expose the cells to
the cobalt cation) indicate that cobalt chloride would also not be
mutagenic in mammalian cells. Although cobalt resinate did not
induce biologically relevant increases in Tkþ/ mutations in L5178Y
cells, cobalt acetyl acetonate induced small colony mutants, which
is indicative of a clastogenic rather than a point mutational effect.
Thus, there is still no convincing or consistent evidence of induction
of gene (point) mutations in either bacteria or mammalian cells
in vitro.
There are several published papers all indicating induction of
MN (Van Goethem et al., 1997; De Boeck et al., 2003a; Miller et al.,
2001; Olivero et al., 1995; Gibson et al., 1997), and possibly also CA
(Olivero et al., 1995), by soluble cobalt salts and ultraﬁne metal
cobalt. These effects were often seen at moderate or low levels of
cytotoxicity and do not appear to be artefacts of excessive toxicity.
No new GLP studies on MN induction in vitro have been performed.
However, the consistency of effects across several publications in-
dicates a real potential to induce genotoxic effects in mammalian
cells. None of these studies investigated whether the MN were due
to a chromosome breakage (clastogenic) or chromosome loss/gain
(aneuploidy) mechanism, although the review by Beyersmann and
Hartwig (1992) mentions that cobalt chloride induced aneuploidy
in human lymphocytes. It is not clear from the summarised results
in which paper these data were originally published. If cobalt salts
are able to induce aneuploidy, then this may contribute to the
positiveMN results. However, in the new studies reported here, CAs
were induced by cobalt acetyl acetonate at modest levels of cyto-
toxicity, by cobalt resinate in the presence of S9 (although the
impact of cytotoxicity is unclear because of precipitation), and by
cobalt oxyhydroxide at a single concentration in the absence of S9,
in the current studies. It is therefore unclear whether the published
positive MN results are due to clastogenic or aneugenic modes of
action, or both. If aneuploidy is involved, such a mode of action is
accepted as exhibiting a threshold (Parry et al., 1994).
There are several published reports of induction of DNA damage
in mammalian cells (mainly using the comet assay) by cobalt metal
and cobalt chloride (Caicedo et al., 2008; Hartwig et al., 1990, 1991;
De Boeck et al., 1998; Van Goethem et al., 1997). However, De Boeck
et al. (2003a) were unable to reproduce the DNA damage responsesNo. of cells examined (MþF) % cells with CA (excluding gaps,
polyploidy and endoreduplication)
M F MþF
1000 0.2 0.2 0.2
900 0.0 0.3 0.1
900 1.8 0.8 1.2
1000 0.8 0.6 0.7
500 1.8 ND 1.8
1000 0.2 0.8 0.5
1000 0.2 0.8 0.5
1000 0.6 0.0 0.3
1000 7.2 11.2 9.2
900 0.3 0.2 0.2
Table 12
Results of analysis of NA and mitotic rate in various tissues during the multi-dose phase of the in vivo study in rats.
Tissue Cobalt sulphate Cobalt monoxide Tricobalt tetraoxide CPA DMH
Increased
NA cells
Decreased
mitotic rate
Increased
NA cells
Decreased
mitotic rate
Increased
NA cells
Decreased
mitotic rate
Increased
NA cells
Decreased
mitotic rate
Increased
NA cells
Decreased
mitotic rate
Non-glandular
stomach
0 þþ 0 þþ 0 0 0 ** 0 0
Glandular
stomach
þþþ þþ* þþþ þþ þ/ 0 0 ** 0 0
Duodenum þþþ þ þþþ þþþ þ/ 0 0 0 0 0
Ileum þþþ þþþ ND ND ND ND 0 0 0 þ/
Caecum þþþ þþþ ND ND ND ND 0 0 0 0
Colon þþþ þþ þþþ þþþ þ 0 þ/ 0 0 0
Rectum þþþ þ ND ND ND ND þ 0 þþ 0
Liver þ þþþ þþ þþþ 0 þ 0 ** þ/ þ/
Lungs þ ND ND ND ND ND 0 ND 0 ND
Urinary bladder þ ND ND ND ND ND þ/ ND þ/ ND
Testis þ/ 0 ND ND ND ND 0 0 0 0
0 ¼ no change.
þ/ ¼ possible increase in NA or decrease in mitotic rate.
þ ¼ slight increase in NA or decrease in mitotic rate.
þþ ¼ substantial increase in NA or decrease in mitotic rate.
þþþ ¼ very substantial increase in NA or decrease in mitotic rate.
ND ¼ no data.
* ¼ possible stimulation of mitosis at low dose, but decrease at high dose.
** ¼ possible stimulation of mitosis at only dose tested.
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sulphate heptahydrate and cobalt octoate also induced DNA strand
breakage, but the damage appeared to be explained by oxidative
damage resulting from reactive oxygen species, probably caused by
the cobalt cation. Such oxidative damage would also be consistent
with the induction of CA, and several authors (e.g. De Boeck et al.,
2003b; Simonsen et al., 2012; Patel et al., 2012) have concluded
that oxidative damage is the main cause of the observed DNA and
chromosomal breakage. However, it is unclear whether the oxida-
tive damage is a primary effect of cobalt, or a secondary effect of
cytotoxicity. In addition, there is evidence from in vitro studies that
cobalt inhibits base and nucleotide excision repair (Hartwig and
Schwerdtle, 2002; Hartwig et al., 2003), damages zinc ﬁngers in
DNA repair proteins (Kopera et al., 2004; Witkiewicz-Kucharczyk
and Bal, 2006) and can also enhance DNA cleavage mediated by
topoisomerase II (Baldwin et al., 2004), which could also contribute
to DNA strand breakage.
The MN, CA and DNA damage-inducing potential of cobalt and
cobalt compounds in vitro has not been conﬁrmed in vivo in the
new studies. No biologically relevant induction of MN or CA has
been found in bonemarrowof rodents treatedwith cobalt sulphate,
cobalt monoxide, tricobalt tetraoxide, cobalt resinate or cobalt
acetyl acetonate in the present studies. Negative results were also
found with cobalt chloride (Gudi and Ritter, 1998), cobalt 2-ethyl
hexanoate (Richold et al., 1981) and cobalt metal (NTP, 2013).
Some of these studies did not include analysis of plasma for pres-
ence of the cobalt compounds under test or cobalt cations. How-
ever, Nation et al. (1983) demonstrated that cobalt chloride
administered orally to rats achieved signiﬁcant exposure levels inTable 13
Chromosomal aberration frequencies in spermatogonia of rats treated with cobalt dichlo
Dose (mg/kg/day) MI No. of cells examined (MþF)
0 1.00 1000
3 1.48 1000
10 1.26 1000
30 1.11 1000
a Historical control range ¼ 0.7e1.5% for group mean CA, excluding gaps.multiple tissues, and, therefore, the in vivo MN and CA studies re-
ported here would have achieved target organ exposures at least
with the soluble compounds. The negative result with cobalt
chloride is interesting since it has been shown to stimulate eryth-
ropoietin production (Goldwasser et al., 1958) which can lead to
increases in spontaneous MN levels (Yajima et al., 1993). If the DNA
and chromosome breaking effects of cobalt and cobalt compounds
in vitro is due to oxidative stress, the more effective anti-oxidant
defences of normal mammalian tissues in vivo may explain the
lack of effects in whole animals. Thus, the genotoxic activity of
cobalt substances, whether it might be based on aneuploidy or
clastogenicity due to reactive oxygen species, appears to have a
threshold which can be exceeded at high concentrations and
extreme conditions in vitro but seems not to be exceeded at high
doses in vivo. A mode of action based on oxidative stress at toxic
exposures may well be important in fully assessing the potential
human risk of exposure to cobalt compounds, and the role of
oxidative stress in carcinogenesis has been elegantly discussed by
Klaunig et al. (2010).
Given the lack of in vivo clastogenicity in somatic cells it would
be expected that cobalt compounds would not produce any geno-
toxic effects in germ cells. The ﬁndings of increased numerical
aberrations in germ cells of Syrian hamsters by Farah (1983) are
therefore unexpected. In contrast to those ﬁndings, in the recent
GLP rat spermatogonial CA study, no polyploid cells were found in
the control or any of the cobalt chloride treated groups from 1000
metaphases per animal scored. In addition, the absence of any
structural aberrations in spermatogonia indicates no clastogenic
activity in germ cells as well as in somatic cells.ride hexahydrate.
Group mean % cells with CA (range) % polyploid cells
Including gaps Excluding gapsa
2.8 (1.5e4.0) 1.1 (1.0e1.5) 0.0
1.3 (0.5e3.0) 0.7 (0.5e1.5) 0.0
2.2 (1.5e2.5) 0.7 (0.5e1.0) 0.0
2.2 (1.5e2.5) 0.9 (0.5e1.5) 0.0
D. Kirkland et al. / Regulatory Toxicology and Pharmacology 73 (2015) 311e338 337In summary, poorly soluble cobalt salts/compounds do not
appear to be genotoxic in vitro or in vivo, at least in tests where the
results can be reliably evaluated. On the other hand, soluble cobalt
salts/compounds and ultraﬁne cobalt metal have produced several
positive genotoxicity results across a range of different in vitro
systems, including chromosomal aberrations, micronuclei, small
colony Tk mutations and DNA damage in mammalian cells,
although they do not convincingly or consistently induce gene (or
point) mutations in either bacteria or mammalian cells. These dif-
ferences are probably due to the availability of free cobalt cations
that can penetrate the cells when soluble compounds are tested.
There is evidence that cobalt salts/compounds induce formation of
reactive oxygen species (ROS), inhibit DNA repair, and enhance DNA
cleavage by topoisomerase, and the fact that the most reproducible
effects seem to be for DNA and chromosomal breakage is consistent
with this. Such a mode of action would be expected to exhibit a
threshold, and the absence of such chromosome damage in robust
GLP studies in vivo suggests that the more effective protective
processes that exist inwhole mammals compared to single cells are
sufﬁcient to prevent DNA damage resulting from reactive oxygen,
even at the high doses tested. Overall, there is no evidence of ge-
netic toxicity with relevance for humans of cobalt substances and
cobalt metal.
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